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Abstract 
Gliomas are amongst the most malignant, invasive and recurrent forms of brain tumour 
with very short survival rate due to high chemoresistance. Recently, highly inducible 
molecular chaperones HSP70 and HSP90 are emerging as important anti-cancer targets. 
Previously, proteomic analysis had demonstrated that post-induction of HSP70 on 
HSP90 inhibition undermines the efficacy of treatment. The present study has quantified 
transcriptional levels and Akt/PKB activity of Hsp70 and Hsp90α in glioma cell lines. In 
order to evaluate the therapeutic value of both chaperones, HSP70 and HSP90 were 
targeted in glioma cells U87-MG using VER-155008 and 17-AAG, respectively. Improved 
efficacy of HSP70 and HSP90 inhibitors was evaluated using a chemosensitivity assay. 
MicroRNAs (miRNAs) are highly conserved small non-coding RNA molecules (21-24 
nucleotides) that regulate simultaneously the expression of hundreds of mRNA targets, 
and are reported to be aberrantly expressed in glioma. Therefore, miRNA microarray 
technology was used to evaluate the efficacy of these inhibitory drugs compared with 
Temozolomide (TMZ) which is used as a standard treatment for glioma. Microarray data 
identified 154 miRNAs using either stringent or non-stringent parameters. 16 miRNAs 
were overlapped with treatments, 15 were upregulated, while 13 were overlapped 
between Temozolomide and VER-155008. In Temozolomide and VER-155008 treatment, 
Hsa-miR-194p was upregulated by 139 and 63 fold, respectively, Hsa-miR-215 was 
upregulated 165 and 61 fold, respectively, Hsa-miR-449a was upregulated by 62 and 77 
fold, respectively and Hsa-miR-744-5p was upregulated by 63 and 43 fold, respectively. 
17-AAG and VER-155008 treatment shown only one miRNA overlapping with 29 and 2 
fold change, respectively. Hsa-miR-4636 was the only downregulated miRNA in TMZ and 
VER treatment with a 32 and 33 fold change, respectively. The miRNA target prediction 
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software was used for the highly upregulated miRNAs:  hsa-miR-194-5p, hsa-miR-215, 
hsa-miR-449a, hsa-miR-744-5p and hsa-miR-3161 correlating to Dnmt3a, Alcam, Cdk4, 
Dnajc16 (Hsp40) and R-Ras2 genes, respectively. Gene validation using qRT-PCR 
suggested no correlation between miRNA-mRNA levels, and thus, challenges the 
suitability of miRNAs technology as treatment predictors. In conclusion, the result for 
the protein data showed that HSP70 was inhibited on treatment with Temozolomide, 
17-AAG and VER-155008 to 13, 0 and 20 %, respectively, while HSP90 inhibition was 84, 
43 and 65 %, respectively, reflecting the affinities of these three compounds towards 
HSP90 compared to HSP70, and therefore infers that HSP70 could be a stronger 
therapeutic approach. In conclusion the result of the study has clearly demonstrated 
that HSP70 can be better therapeutic biomarker for treatment of glioma. 
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1.1 Molecular chaperones 
In the cellular environment, a set of functional proteins are required to maintain the 
normal functioning of the cell. The amino acid sequences of these proteins fold itself 
into the native state to accomplish a variety of functions. However, due to the highly 
crowded nature of the cellular environment, newly synthesised proteins have a high 
probability of misfolding or aggregating (Houry et al., 2001). It is essential to ensure the 
efficiency and accuracy of the protein folding process in order to form active protein 
conformations. Molecular chaperones play key role in several processes (Figure 1.1). 
Molecular chaperones are proteins that stabilise conformation of unstable polypeptides 
(proteins) by regulating binding and release cycles, which facilitate the correct 
conformational folding and prevent aggregation. They are also essential for protein 
translocation and normal protein turnover (Whitesell et al., 2005).  
 
Figure 1.1: Role of molecular chaperones. Above figure describes different role of 
multiprotein complex (Taken from Whitesell et al., 2005). 
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1.2 Heat Shock Proteins 
In stress-like conditions, intracellular milieu induces stress responses inhibiting the 
activity of housekeeping genes and activating stress genes. This condition results in a 
group of molecular chaperones being activated. These molecular chaperones are 
termed stress-proteins or heat shock proteins (HSPs). They are a group of highly 
conserved and ubiquitous molecular chaperones initially identified on the basis of their 
amplified synthesis on exposure to elevated temperatures. This observation was first 
reported by Ritossa in 1962 (Ritossa et al., 1962; Stephanou et al., 2011). They comprise 
of approximately 5-10% of the total protein content in a normal healthy cell (Soo et al., 
2008). A cellular insult such as heat, hypoxia, starvation, sodium arsenite exposure, virus 
transformation or radiation are associated with induction of protein misfolding or 
aggregation (Graner et al., 2005). These misfolded or aggregated proteins bind to 
molecular chaperones causing the release of heat shock factors (HSF), a transcription 
factor, which activates heat shock element (HSE), located on Hsp promotor gene leading 
to induced HSP concentration. HSPs functions to prevent protein aggregation, induce 
solubilisation of loose protein aggregates, and escorts denatured polypeptides for 
proteolytic recycling (Ahner et al., 2005; Calderwood et al., 2006). They participate in 
refolding of proteins which have been damaged, and sequester damaged proteins and 
target them for degradation. HSPs are mainly classified and defined according to their 
molecular weights namely (as shown in Table 1.1): HSP100 (100kDa), HSP90 (90kDa), 
HSP70 (70kDa), HSP60 (60kDa), HSP40 (40kDa) and small HSPs (sHSP) with a molecular 
size ranging between 15 to 30 kDa (Soo et al., 2008; Powers et al., 2012). On the basis 
of location, they accomplish different functions. HSPs with high molecular weights are 
ATP-dependent as they assist newly synthesised or damaged proteins in ATP-dependent 
processes, while HSPs of low molecular weight function as ATP-independent proteins 
21 
 
(Soo et al., 2008). The overexpression of both HSP70 and HSP90 has been reported in 
solid tumours and haematological malignancies. The presence of HSPs also contributes 
towards the survival of malignant cells by maintaining protein homeostasis and also 
helps in tolerating genetic alterations. Apart from cancers, HSPs are also expressed in 
diseases such as Alzheimer’s, Huntington’s, amyotrophic lateral sclerosis and 
cardiovascular diseases, thus, targeting HSPs is of therapeutic importance (Mahalingam 
et al., 2009; McConnell et al., 2013).  
HSP70 and HSP90 can be therapeutic targets in glioma therapy since they are found to 
interact with hallmarks of cancer proposed by Hanahan and Weinberg. These hallmarks 
are (i) self-sufficient in growth signalling; (ii) insensitivite to anti-growth signalling; (iii) 
able to evade apoptosis; (iv) sustain angiogenesis; (v) tissue invasion and metastasis; 
and (vi) limitless replicative potential (Hanahan et al., 2011). This research focuses on 
HSP70 and HSP90α as they are abundantly present in various cancers.  
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Table 1.1: Classification and role of heat shock proteins. 
Family Subunits Location Functions References 
HSP90 HSP90α, 
HSP90β, 
HSP90N and 
TRAP-1 
Cytosol, mitochondria and 
nucleus 
Play a role in signal transduction by interacting with steroid hormone 
receptors, tyrosine kinases, serine/threonine kinases; refold and maintain 
proteins in vitro; auto-regulation of the heat shock response; role in cell 
cycle and proliferation. 
(Sato et al., 
2000) 
HSP70 HSC70, HSP72, 
GRP75 and 
GRP78 
Cytosol and nucleus Anti-apoptotic activity; refolds and maintains denatured    proteins in vitro; 
role in signal transduction, cell cycle, proliferation and intracellular 
transporting; interacting with nascent chain polypeptides; auto-regulating 
heat shock response; potential antigen-presenting molecule in tumour 
cells. 
(Goloudina et 
al., 2012) 
 
HSP60 HSP60 Cytoplasm, mitochondria, 
nucleus and Endoplasmic 
reticulum 
Refolds and prevents aggregation of denatured proteins in vitro; acts as 
cofactor in proteolytic systems and facilitate protein degradation 
(Lim et al., 
2005) 
HSP40 HSP40 Cytosol Plays a role as co-chaperone of HSP70 to enhance ATPase   activity (Fan et al., 
2003) 
HSP27 HSP27 Cytosol and nucleus Anti-apoptotic activity; Suppresses aggregation and heat inactivation of 
proteins in vitro; anti-apoptotic activity. 
(Lim et 
al.,2005) 
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 HSP70 
HSP70 (Heat shock protein 70kDa) is one of the major molecular chaperones which is 
ubiquitous and present throughout prokaryotes to eukaryotes. There are atleast 8 genes 
found that code for HSP70 family (Barnes et al., 2001; Davis et al., 2013). Isoforms of the 
HSP70 family are present in different locations in the cell. Their functions differ 
according to their location. Constitutively expressed isoform heat shock cognate 
(HSC70) and stress-induced form HSP70 are two major isoforms located mainly in the 
cytoplasm while other HSP70 isoforms, mortalin is located in the mitochondria and 
GRP78 is found in the endoplasmic reticulum (Barnes et al., 2001; Chatterjee et al., 
2012). They play important roles of chaperoning in de novo synthesis (Nicolaı et al., 
2010) and function by assisting nascent protein folding, preventing protein aggregation 
and protein assembly (Massey et al., 2010). They also act as co-chaperones to the major 
multiprotein complex HSP90 and function by assisting in the substrate loading phase 
(Davis et al., 2013).  
 
 
Figure 1.2: Diagrammatic representation of HSP70 conformational activity. (Blue 
structure represents HSP70, NBD= Nucleotide Binding Domain, SBD = Substrate Binding 
Domain) (Taken from Powers et al., 2012).  
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HSP70 proteins comprise of two functional regions, N-terminal nucleotide binding 
domain (NBD) and a substrate binding domain (SBD) and both of these domains act 
interdependently.  N-terminal NBD (44 kDa) has ATPase activity and binding site for 
HSP70 co-chaperones. It connects to the C-terminus (27 kDa) which is composed of the 
SBD and a “lid” region by conserved linkers (Javid et al., 2007). HSP70 forms large multi-
protein complexes with various co-chaperones including BAG-1 (BCL2-associated 
athanogene), HIP (HSC70 Interacting protein), HOP (HSP90/HSP70 Organising Protein), 
HSP40 (Heat shock protein 40 kDa, HSPBP1 and CHIP (C terminus of HSC70-Interacting 
Protein) in order to undergo chaperoning (Massey et al.,2010). This chaperoning activity 
is dependent on the ATP hydrolysis cycle (Figure 1.2). HSP70 chaperone complex forms 
‘open state’ when ATP is bound to the NBD and the lid segment of C-Terminus develops 
low affinity for substrate binding. ATP stimulates peptide binding at SBD inducing 
conformational change to form ‘close state’ and thus resulting in increased affinity for 
peptide substrate binding. This also leads to an increase in the interaction of NBD with 
co-chaperone HSP40. HSP70 and HSP90 chaperone activity assists substrate maturation 
by simultaneously interacting with TPR (tetratricopeptide repeat) domain co-
chaperones (HOP, CHIP) at the C-terminus of both chaperones. This process is essential 
for the assembly of both chaperones. To release a peptide substrate, ATP undergoes 
hydrolysis to form ADP by the interaction of BAG-1 (nucleotide exchange factors) (Jego 
et al., 2010; Nicolaı et al., 2010; Powers et al., 2012). Thus, along with ATPase activity 
and peptide binding activity, the HSP70 co-chaperone plays an important role in HSP70 
activity and protein substrate specificity (Zylicz et al., 2001). Heat shock proteins are 
induced due to stress such as heat shock, hypoxia or cancer. In non-stress conditions 
they play roles as normal molecular chaperones. In normal cellular environments, HSC70 
is abundantly expressed while HSP70 is expressed at low basal levels but both are over 
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expressed in stress conditions which are related with protein misfolding disorders 
(Nicolaı et al., 2010). Their elevated levels are the outcome of activation of transcription 
factors HSF-1 and HIF-1α. It has been reported that HSP70 isoforms are overexpressed 
in various cancers (Beere et al., 2000; Nylandsted et al., 2000). HSP70 is also involved in 
various pathologic conditions such as neurodegenerative diseases and ischemia, 
inflammatory processes and immunogenicity. In Multiple Myeloma (MM) cells, HSP70 
was found to be strongly upregulated on pharmacological inhibition of HSP90 
(Chatterjee et al., 2012). Evidence shows that HSP70 suppresses apoptosis activity and 
controls cell cycle and cell growth (Beere et al., 2000). HSP70 inhibits apoptosis both 
upstream via cytochrome-C and Apoptosis–inducing factor (AIF) release and 
downstream by caspase-3 activation (Guo et al., 2005). HSP70 inhibits apoptosis in U937 
lymphoma cells by preventing caspase-3 activation in the presence of active 
Cytochrome-C (Aghdassi et al., 2007). HSP70 inhibits apoptosis via TRAIL (TNF-related 
apoptosis inducing ligand) pathway in colon cancer and in cardiomyocytes (Demidenko 
et al., 2006). In addition, HSP70 has the ability to inhibit apoptosis by caspase 
independent pathways, preventing DNA fragmentation by interacting with apoptosis 
inducing factor (AIF) (Li et al., 2000; Guo et al., 2005). Thus, HSP70 with its anti-apoptotic 
activity encourages cell viability even in malignant cells. As mentioned earlier, various 
studies have confirmed the expressions of HSP70 in cancers and other diseases. HSP70 
acts as co-chaperone to HSP90 forming multi-chaperone complex which is involved in 
folding and maturation of several key proteins and cancer progression (Shervington et 
al., 2008).  
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 HSP90  
Heat shock protein 90 (HSP90) is one of the most abundant proteins found in both 
prokaryotes and eukaryotes (Mehta et al., 2011). It is involved in various cellular 
processes including signal transduction, protein folding, protein degradation. It plays an 
important role in the folding of newly synthesized proteins and the stabilization and 
refolding of denatured proteins after stress. The chaperone HSP90 family is further 
classified as cytosolic HSP90α, HSP90β and HSP90N, endoplasmic reticulum GRP94 and 
mitochondrial TRAP-1 (Sreedhar et al., 2004). HSP90α expression is highly inducible 
while HSP90β is considered to be constitutively expressed. Under non-stress conditions, 
it comprises of 1-2 % of total cellular proteins while it increases by 4-6 % under stress 
conditions (Gallerne et al., 2013). The high expression levels of HSP90α has been 
associated with tumour progression, enhanced cell cycle regulation and induced cell 
signalling via tyrosine kinases.   
 
Figure 1.3: Schematic diagram showing the HSP90 ATPase activity. (Pink structure 
represents HSP90) (Taken from Centenera et al., 2013).   
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HSP90 is a homodimer composed of three functional domains: an N-terminal ATP 
binding domain, a middle domain having an affinity for client protein binding and C-
terminal dimerization domain which regulates ATPase activity as it contains the 
tetratricopeptide repeat-binding (TRP) motif, EEVD (Javid et al., 2007). Since HSP90 
exists as a large multi-chaperone complex, it simultaneously interacts with co-
chaperones such as activators of HSP90 ATPase protein 1 (AHA1), HSP70/HSP90 
interacting protein (HIP), HSP90 organising protein (HOP), and Tumor protein (p23) to 
maintain the conformational maturation and stability of key signalling molecules 
involved in cell proliferation, survival, and transformation via sequential binding or 
release of involved co-chaperones (Massey et al., 2010). HSP90 chaperone complex 
cycle involves an open and close state. In the open state, HSP90 in the absence of ATP 
recruits co-chaperone that assist in client proteins binding. During ATP binding, HSP90 
undergoes conformational changes to form the closed state which functions as a clamp 
that holds client proteins and opens on ATP hydrolysis resulting in client proteins being 
released (Figure 1.3) (Xiao et al., 2006; Jego et al., 2010). The overexpression of heat 
shock proteins has been reported in various diseases such as breast cancer, lung cancer, 
leukaemia, and Hodgkin’s disease (Jolly et al., 2000).Over 200 client proteins of HSP90 
are involved in this event, maintaining cell survival and thus HSP90 is significant in 
various cellular functions (Picard et al., 2002; Centenera et al., 2013). Many of the client 
proteins, such as steroid receptors, epidermal growth factor receptor (EGFR) family 
members, the MET oncogene, RAF-1 kinases, Akt kinase, BCR-ABL, mutant p53, cyclin 
dependent kinase 4 (CDK4), hypoxia-inducible factor 1α (HIFα), and matrix 
metalloproteinase 2 (MMP2), are known to be involved in cancer signalling pathways, 
thus they are also known as oncoproteins. The role of HSP90 makes it promising target 
for anti-cancer treatment (Xiao et al., 2006).  
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 HSP70/HSP90 co-chaperones  
The heat shock protein families accomplish cellular function along with co-chaperone 
and clients proteins. The co-chaperones and client proteins are important for 
maturation of their complexes. HSP70 and HSP90 are involved in various cell survival 
pathways. HSP90 is a multi-chaperone complex and the HSP70 form co-chaperones to 
HSP90. Similarly, HSP40 acts as co-chaperone to HSP70 for chaperoning proteins. While 
BAG-1, HIP, HOP and CHIP are client proteins of HSP70 (Macias et al., 2011), HSP90 has 
more than 100 known client proteins (Table 1.2) (Picard et al., 2002). HSP90 client 
proteins are also known as oncoproteins due to their interaction in oncogenic signalling 
pathways (Xiao et al., 2006). These client proteins bind on to the N-terminal of protein 
structure (An et al., 2000). The roles of some of these client proteins are as follows: 
 BAG-1 
BAG-1 promotes cell survival (Townsend et al., 2005). It was the first protein to be 
identified to regulate cell survival by binding BCL-2. BAG is a nucleotide exchange factor 
in the HSP70 chaperoning cycle. Most tumours show an elevated overexpression of 
BAG-1 which leads to inhibition of apoptosis and isolation of the death domain (DD) 
protein, FADD (Fas-Associated protein with Death Domain), resulting in the inhibition of 
anoikis (Programmed cell death). It also interacts with RAF pathway to enhance cell 
survival (Cutress et al., 2002).  
 AKT 
Akt is present in HSP90 complexes co-chaperone with HSP70 and other client proteins. 
It prevents apoptosis by activating nuclear factor- κB (NF-κB) and enhances cell 
proliferation by phosphorylation and inactivation of signalling molecules such as BAD 
and caspase-9. Breast cancer cells are found to be resistant to chemotherapy due to Akt 
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activated by HSP90/HSP70 complexes. Thus, HSP inhibitors such as ansamycins can 
downregulate Akt activity by inhibiting the Akt-dependent pathway (Sato et al., 2000; 
Basso et al., 2002). 
 RAS/RAF (ERK) Pathway 
Evidence shows that the ERK pathway is important in signalling since it promotes cell 
proliferation, cell survival and metastasis. RAF kinases participate in the ERK pathway. 
A-Raf, B-Raf and C-Raf are members of RAF kinase family. This pathway is abnormally 
activated in cancer by upstream activation of epidermal growth factors and also leads 
to activation of mutated B-Raf. A-Raf and C-Raf are required for the stability of the 
HSP90 complex. Mutated B-Raf and N-Ras (components in ERK pathway) are observed 
in malignant melanoma. Inhibiting HSP90 disrupts the complex and reduces the level of 
ERK signals (Grbovic et al., 2006). 
 ErbB2/HER-2  
It is a type of Tyrosine kinase that is overexpressed in prostrate, gastric, ovarian and 
breast cancers. The human epidermal growth factor receptor-2 (HER-2) is a kinase 
receptor which acts as a client protein to HSP90. Therefore, it plays role in mainting 
stability of HSP90 mature complex and in cell regulation. Thus, Inhibiting the activity of 
HSP90 by ansamycin (HSP90 inhibitory compunds) causes degradation of the signalling 
molecules involved in cancer growth (Solit et al., 2002).  
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Table 1.2: Client proteins and their interaction with heat shock proteins (Taken from 
Macias et al., 2011). 
 
Chaperones Cellular functions Co-chaperone Interaction proteins 
HSP70 
Signal transduction 
BAG-1 
BAG-1 
Raf-1 Kinase 
Growth factor responses 
Hormone response 
BAG-1 
HIP 
Hormone receptor 
Steroid receptor 
Cell death 
BAG-1 
Unknown 
BCL-2 
APAF-1 
Stress response Unknown HSF-1 
Complex assembly 
HOP 
HDJ1 
Chaperone complex 
Chaperone complex 
HSP90 
Signal transduction CDC37 Kinases 
Hormone response 
PP5 (TPR) 
Immunophilins (TPR) 
CyP40 
FKBP52 
FKBP51 
Gluococorticoid receptor 
Hormone receptor 
Oestrogen receptor 
Steroid receptor 
Progestrone receptor 
Cell death Unknown APAF-1 
Stress response Unknown HSF-1 
Complex assembly 
p23 
HOP 
Chaperone complex 
Chaperone complex 
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These are a few of client proteins that are responsible for cancer cell survival but many 
such associated client proteins can cause aberrant disease. These important client 
proteins play a role in chaperoning as HSP70 co-chaperones HSP90 which is a multi-
chaperone complex. Moreover, the stabilization and activation of these chaperones 
requires client proteins that act as co-chaperones for protein folding and cellular 
activity. 
 
Figure 1.4: Diagram showing inhibition of HSP70/HSP90 machinery (Taken from 
Mahalingam et al., 2009).  
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HSP70 has been reported to play a key role in the HSP90 chaperone machinery. This 
HSP90 machinery maintains protein stability and activity of new synthesised proteins. 
During  induction of stress, heat shock element (HSE) activates Heat shock factor-1 
(HSF1) resulting I n the transcription of heat shock proteins. HSP90 complex comprised 
of co-chaperone HSP70 with other client proteins HOP and HSP40 forms ‘open state’ 
which results in possessing a higher affinity for client proteins and recruits client proteins 
such as Cyclin dependant kinase 4 (CDK4). The matured complex or ‘Closed state’ is 
formed due to phosphorylation by co-factors such as AHA1. On formation of the mature 
complex, recruited client proteins are activated resulting in cellular stress such as Akt 
phosphorylation, ERK activation, expression of oncogenes. Therefore, inhibiting 
phosphorylation or ATP binding may lead to proteosome degradation, thereby, 
preventing cell survival and cell proliferation (Figure 1.4) (Pearl et al., 2006).  
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1.3 Heat shock protein inhibition as anticancer therapeutic target 
HSP70 and HSP90 co-operate to maintain tumour cell survival (Zorzi et al., 2011; 
Chatterjee et al., 2012; Centenera et al., 2013; Fawzy et al., 2013). Targeting these 
proteins and their client proteins can be of therapeutic importance. Geldanamycin , a 
first generation of HSP90 inhibitor, is ansamycin-derivative benzoquinone compound 
that blocks the HSP90 activity by binding to ATP-binding site on the HSP90 N-terminal 
domain while Radicicol, another HSP90 inhibitor, targets the ATP binding site on the N-
terminal domain of HSP90. Its hepatotoxicity prompted the discovery of its derivatives 
17-AAG (Tanespimycin) and 17-DMAG, among which 17-AAG has lowest toxicity 
compared to other derivatives of Geldanamycin. Thus, has been successfully cleared 
Phase 1 clinical trials and is undergoing Phase 2 testing. Various studies have shown 
effectiveness of combinational treatment by targeting both HSP90 and HSP70. There are 
a few examples of HSP70 inhibitors categorised into three basic forms namely protein 
aptamers, small molecule inhibitors, and antibody treatments. Aptamers are designed 
to disrupt HSP70 function via NBD/SBD binding. In HeLa cells, combinational treatment 
using HSP70 aptamers A17 and 5-FU (5-fluorouracil) or Cisplatin reported enhanced cell 
survival (McConnell et al., 2013). HSP70 can inhibit apoptosis by directly neutralizing the 
caspase-independent death effector, apoptosis inducing factor (AIF). Thus, peptide 
aptamers are developed with an ability to inhibit HSP70 function by acting as a substrate 
mimetic peptides such as ADD70 (AIF-Derived Decoy for HSP70) that has the ability to 
sequester inducible HSP70 by interacting with the peptide binding region of HSP70 and 
thereby avoiding binding  AIF and other client proteins (Rerole et al., 2011). There are 
small molecules which are target specific inhibitors, such as Pifithrin-μ (PFT-μ), MKT-007 
and VER-155008. Previous studies have shown effect of PFT-μ in leukemic cell lines in 
combination with other chemotherapeutic agents such as 17-AAG (Kaiser et al., 2011). 
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Recent study have demonstrated a synergistic effect of 17-AAG in combination with 
HSP70 inhibitor PFT-µ in bladder cancer and thus, suggest HSP70 as molecular target for 
HSP90 resistance (Ma et al., 2014). MKT-007, a specific HSC70 inhibitor, also has an 
ability to bind actin. MKT-007 was identified as an anti-tumour agent during Phase 1 
clinical trials but failed Phase 2 due to renal toxicity (McConnell et al., 2013). 
Combinational treatment of VER-155008 with 17-AAG demonstrated to be effective in 
the treatment of multiple myeloma (MM) and also in human colon cancer (HCT-116) 
cells. RNA interference (RNAi) has emerged as new approach for cancer treatment.  
Reports have shown the regulation of HSPs using small interfering RNA (siRNA) to induce 
chemosensitivity in cancer (Cruickshanks et al., 2010; Mehta et al., 2013). However, this 
research will focus on targeting HSP70 using selective compounds namely 17-AAG & 
VER-155008 (Table 1.3) (Patel et al., 2008; Thakkar et al., 2011). 
Table 1.3 Binding targets of heat shock protein compounds. (NBD: Nucleotide Binding 
Domain; SBD: Substrate Binding Domain) (Taken from Kaiser et al., 2011; McConnell et 
al., 2013).  
Chaperones Compounds Binding targets 
HSP70 
A17-aptamer NBD 
ADD70 SBD 
MKT-007 NBD 
Pifithrin-µ NBD 
VER155008 (VER) SBD 
HSP90 
17-AAG NBD 
17-DMAG NBD 
Geldanamycin NBD 
Novobiocin NBD/SBD 
Radicicol NBD 
  
35 
 
 17-AAG 
Geldanamycin (GA) is a naturally occurring benzoquinone ansamycin antibiotic which 
blocks the nucleotide binding pocket by binding to the N-terminal of HSP90 with high 
specificity. It inhibits HSP90 ATPase activity by disrupting the stable complex, thereby 
preventing cell proliferation. In a similar manner, it also inhibits the cell survival process 
in normal cells (An et al., 2000). The high concentration of HSP90 is responsible for the 
high accumulation of GA in tumour tissue (Graner et al., 2005). One of the HSP90 
inhibitors and analogues of GA, namely, 17-AAG (17-aminoallylgeldanamycin) (Figure 
1.5) has been shown to down regulate HSP90 client proteins in animal xenograft models 
and has also been reported to be involved in cancer stabilisation, decreased cell 
proliferation and a reduction in apoptosis (Xiao et al., 2006). 17-AAG has been found to 
be more effective than GA since it is less cytotoxic, though it binds with lower affinity 
but shows 100 times more affinity to HSP90 in cancer cells compared to normal cells 
(Soo et al., 2008). 17-AAG was the first-in-class HSP90 inhibitor to enter clinical trials in 
both adult and paediatric patients and is presently in phase II/phase III clinical trials in 
adults (Gaspar et al., 2009). Previous studies have shown that HSP90 was inhibited using 
17-AAG and proteomic studies showed that on inhibition of HSP90, HSP70 was 
upregulated (Munje et al., 2011). Thus, HSP70 is emerging as a molecular target for 
cancer treatment.  
Figure 1.5: Chemical structures of geldanamyacin and its analogue, 17-AAG (Taken 
from Gava et al., 2009).   
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 VER-155008 (VER) 
VER-155008 (VER) (Figure 1.6) binds to HSP70 at very low concentrations and it also 
binds to other members of HSP70 family such as HSC70 and GRP78. It effectively binds 
HSP90β isoforms (Macias et al., 2011). VER-155008 blocks HSP70 activity by binding to 
the ATPase pocket of HSC70/BAG-1 and the N-terminal domain, inhibiting cell 
proliferation. VER-155008 also induces apoptosis via both caspase 3/7 dependent and 
independent pathways (Massey et al., 2010). It has also reported that VER-155008 
targets HSP90 client protein degradation such as RAF-1 and HER2 in human colon 
carcinoma (HCT116 and BT474 cells). VER-155008 effectively arrests cells in G1-phase at 
low concentrations while at higher concentrations causes G2/M Phase arrest (Massey 
et al., 2010). In myeloma cells, VER-155008 decreases cell viability and proved effective 
when treated in conjunction with HSP90 inhibitory compounds. When investigated in 
vivo (in tumour mice), it showed limited absorption, thus it is administered via the IV 
route (Massey et al., 2010; McConnell et al., 2013). 
 
 
Figure 1.6: Chemical structure of VER-155008 (Taken from McConnell et al., 2013). 
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 Temozolomide (TMZ) 
The standard treatment of glioblastoma multiforme (GBM) involves chemotherapy, 
radiotherapy and surgical resection. Due to its aggressive nature, it is a challenge to 
eradicate glioblastoma. TMZ has emerged as an effective chemotherapeutic agent 
which is capable of increasing survival rates after diagnosis. TMZ, a 3-methyl derivative 
of mitozolomide, (Figure 1.7) is a second generation DNA methylating agent which is 
less toxic than derivatives of mitozolomide. It was first synthesized at Aston University 
in 1984 (Ohba et al., 2010). Under physiological conditions, it undergoes spontaneous 
conversion to the active alkylating MTIC (5-(3-methyltriazen-1-yl) imidazole-4-
carboximide). TMZ is used as a chemotherapeutic agent in the treatment of pancreatic 
cancer, melanomas and gliomas with fewer side effects compared to other anti-cancer 
reagents. It has the ability to cross the blood-brain barrier and has a 100% bioavailability 
when administered orally. The major disadvantage in the use of TMZ treatment is drug 
resistance developed as a result of DNA repair enzyme MGMT which transfers methyl 
group of O6-methylguanine in DNA to Cysteine, thus rendering cells to TMZ resistance 
(Marchesi et al., 2007; Gaspar et al., 2010; Ohba et al., 2010b; Pan et al., 2012). 
 
Figure 1.7: Chemical structure of TMZ (Taken from Marchesi et al. 2007). 
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1.4 MicroRNA 
miRNAs (19-22 nt) are conserved small non-coding RNA (Bartel et al., 2009). They were 
first discovered in 1993 while studying small endogenous non-coding RNA lin-4, which 
regulates larval cell development in Caenorhabditis elegans. It has been reported that 
instead of coding for its protein, lin-4 produces small RNA which further mediates 
repression of lin-14 protein without affecting mRNA levels. Similar phenomena were 
reported in let-4 which regulates transition cell development in larvae. Further studies 
reported miRNA genes in various species from flies, worms to humans. Due to the 
increasing number of identified miRNA, miRNA repository of published miRNA 
sequences was created and developed by Sam Griffith-Jones from the Wellcome Trust 
Sanger Institute known as miRBase. Today in miRBase online registry, there are more 
than 1900 mature human miRNA sequences (Bartel et al., 2004; Bartel et al., 2009; 
Kozomara et al., 2014). According to the nomenclature guideline of miRBase databases 
3 or 4 letters designate the species name, for instance hsa for Homo sapiens, followed 
by the sequence designation miR as mature sequence and the assigned unique 
identification number. In some cases, they are further followed with suffixes such as 
miR-146a or miR-146b which indicate the distinct sequences for same transcripts. 5p or 
3p denotes the location of mature miRNA at 5’arm or 3’arm of the precursor miRNA. 
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Figure 1.8: Biogenesis of miRNA The above figure shows canonical maturation of miRNA 
maturation which includes Primary miRNA transcript (Pri-miRNA) production by RNA 
polymerase II or III and formation of Pre-miRNA in the nucleus after cleavage of Pri-
miRNA by microprocessor complex Drosha-DGCR8 (Pasha). Pri-miRNA are transported 
to cytoplasm by Exportin-5-Ran-GTP and cleaved by Dicer/TRBP to form mature miRNA 
duplex. Further, Functional strand is loaded into RNA-induced silencing complex (RISC) 
by Argonaute (Ago2), where it guides RISC to silence targeted mRNAs by either mRNA 
cleavage, translational repression or de-adenylation while passenger strand is degraded 
(Taken from Bartel et al., 2009).  
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 Biogenesis of miRNA  
Most of miRNAs can be encoded within an exon of a unique transcript, occurring as 
“Polycistronic” miRNAs, or can be found within the introns of protein coding or non-
coding genes. About 40% of miRNA are encoded in the introns, while 10% in the exons 
(O'Carroll et al., 2013). Irrespective of the genomic locations, miRNA biogenesis initiates 
with transcription using RNA polymerase II, processing a primary miRNA transcript (pri-
miRNA) ranging from hundreds to thousands of nucleotides in length and folds to form 
imperfectly paired double stranded stem loop structure. Pri-miRNA is processed to 
mature miRNA by ribonuclease III (RNAse III). During the first step, DGCR8 (Digeorge 
syndrome critical region 8) identifies and binds to the stem region of the pri-miRNA, 
functions as a molecular ruler to determine the precise cleavage site. Then, Pri-miRNA 
recruits Drosha enzyme which cleaves 5’ and 3’ arm of the pri-miRNA hair pin structure 
to form Pre-miRNA (Pellegrino et al., 2013). The nuclear export factor Exportin-5 binds 
the pre-miRNA and transports it to the cytoplasm and also protects pre-miRNAs against 
nuclear digestion. Exportin-5 recognises the pre-miRNA independently of its sequence 
or the loop structure, where the second RNase III, Dicer, processes the pre-miRNA into 
a 21 nt long miRNA/miRNA* duplex. The trans-activator RNA (tar)-binding protein 
(TRBP) enzyme also participates in the process of Pre-miRNA cleavage by forming a 
complex with the Dicer enzyme. The miRNA/miRNA* duplex is further processed or 
unwound by members of Argonaute (AGO) family which further loads into the RNA-
induced silencing complex (RISC) participating in post-transcriptional regulation. Human 
genome encodes four AGO proteins (AGO 1-4) which forms part of RISC and are found 
to bind miRNAs with mRNA targets. Only one strand of the duplex will become the 
mature miRNA while strand (miRNA* or passenger strand) with less tightly paired 5’ end 
is degraded (Figure 1.8) (O'Carroll et al., 2013).   
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 Gene Regulation 
MicroRNA can direct the RISC to downregulate gene expression by either of two post-
transcriptional mechanisms: mRNA cleavage or translational repression. Once the 
miRNA is incorporated in cytoplasmic RISC, further mechanism is carried out depending 
on complementarity of seed sequences. The full complementarity between miRNA and 
its mRNA targets will lead to mRNA cleavage and destruction by endonucleolytic activity 
of AGO2 protein or lead to translation repression in the absence of complementarity or 
insufficient group of complementarity. Both siRNA and miRNA cleave mRNA in a similar 
manner (Bartel et al., 2009). The miRNA has the ability to regulate the cleavage of 
siRNA/mRNA duplexes with partial complementarity which prevents mRNA cleavage. 
These miRNAs have 2 – 7 bases which are complementary sequences, known as ‘seed’ 
sequence, responsible for target recognition. These bases must pair with the 3’ 
untranslated region (3’UTR) complementary mRNA target bases which lead to 
translational inhibition and silencing of the targeted message (Su et al., 2014).  
 Biological functions 
Studies have shown that the miRNA exists not only in human cells (Zhu et al., 2011), but 
also in serum, plasma, saliva, milk and tears (Zhu et al., 2011; Zhang et al., 2012) since 
they constitute an appropriate environment for circulating or transporting them to 
targeted sites for regulating physiological and pathological processes (Kosaka et al., 
2010; Zhang et al., 2010). They are known to have the potential to transfer from plants 
via regular dietary consumption (Zhang et al., 2012). Recently, proteomic studies 
reported the impact of a single miRNA on hundreds of mRNA targets. Referring to 
biogenesis of miRNA, its shows the potential to target hundreds of mRNA sequences 
simultaneously due to its efficient ability to regulate by binding to the 3’UTR region. 
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Thus, regulating thousands of mRNAs modulates gene expression by regulating cellular 
signalling pathways such as apoptosis, proliferation, cell cycle, differentiation, stem cell 
maintenance and metabolism.  
Over the past few decades, investigations have highlighted the diversity of altered 
miRNAs that contribute to the pathogenesis of solid tumours and haematological 
malignancies. The miRNAs may act as potential ‘oncogenes’ by either targeting tumour 
suppressors or acting as ‘tumour suppressors’, on their functional damage such as 
genomic deletion, mutation, epigenetic silencing, and/or miRNA processing alteration; 
and thus play crucial roles in the development and progression of cancers (Griffiths-
Jones et al.,2008). Some of the alterations are found in various cancers while others are 
type-specific. miRNAs can target various mRNAs but at the same time different miRNA’s 
or its family may regulate one mRNA target. In A549 NSCLC (Non-Small Cell lung Cancer) 
cell lines, miR-29 acts as a tumour-suppressor but in breast cancer cells they play 
oncogenic functions (Fabbri et al., 2007). In breast cancers, miR-155 acts as oncogene 
and is upregulated. The miR-373 and miR-520c regulate prognosis in breast cancer 
patients by inversely regulating CD44 isoform while miR-10b regulated tumour invasion 
by TWIST1 (Bartels et al., 2009). Similarly, miR-26a down regulates in HCC 
(Hepatocellular Carcinoma) to induce apoptosis while it’s up regulation and 
overexpression causes metastasis in glioma or NSCLC (Non-small Cell Lung Cancer) (Huse 
et al., 2009; Kota et al., 2009; Liu et al., 2009). Thus, studying the role of miRNAs in 
cancers is complicated due to this functional diversity. This direction of research 
involving the identification of dysregulated miRNA profiles has been coined out on 
various cancers such as lung cancer (Takamizawa et al., 2004), breast cancer (Iorio et al., 
2005), papillary thyroid carcinoma (He et al., 2005), gastric carcinoma (Michael et al., 
2003) and colon cancer (Cummins et al., 2006). For example, miR-155 is over-expressed 
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in various different cancers (Kluiver et al., 2005; Volinia et al., 2006; Li et al., 2013; 
Rozovski et al., 2013). Studies showed association of miRNAs with the hallmarks of 
cancer (see Figure 1.9) by interacting with development, invasion, differentiation, 
metabolism, metastasis and apoptosis (Chou et al., 2013). miRNAs are reported to 
overlap with sets of genes by sharing similar seed sequences, known as families. The 
miR-34 family (miR-34a, miR-34b and miR-34c) is known to mediate tumour suppression 
by modifying p53 and inhibiting invasion and metastasis in various tumours (Yamazaki 
et al., 2012; Javeri et al., 2013). In addition, miR-17-92 clusters (miR-17-5p, miR-17-3p, 
miR-18a, miR-19a, miR-20a, miR-19-1, miR-92-1) that are overexpressed can be a 
biomarkers for multiple myeloma and B-cell lymphoma (He et al., 2005; Gao et al., 
2012). However, in some miRNAs such as miR-26a, miR-129, miR-143 and miR-145 that 
are downregulated in cancer such as breast cancer, prostate cancer, cervical cancer, 
lymphocytic malignancy and colorectal cancer where they promote cancer stem cell or 
cell proliferation and migration (Michael et al., 2003; Karaayvaz et al., 2013; Su et al., 
2014). The reduced expression of miR-206 and 29b along with enhanced miR-126 and 
miR-335 expression, inhibits cancer development and inhibit metastasis in breast cancer 
cell lines (Negrini et al., 2008; Pellegrino et al., 2013). 
 miRNAs in glioma  
Glioblastoma multiforme is grade IV brain tumour and accounts for approximately 70% 
of all diagnosed gliomas with approximately 3 % survival rate. Due to its highly invasive 
nature complete removal of the tumour is challenging. Research has shown that 50% of 
miRNAs are expressed in the mammalian brain (Lagos-Quintana et al., 2002; Krichevsky 
et al., 2003). Amongst 180 screened miRNAs, dysregulation of 8 miRNAs in glioblastoma 
has been reported using microarray (Chan et al., 2005; Ciafre et al., 2005). The miR-21 
was the most common to be reported as an anti-apoptotic factor. miR-21 reported to 
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target p53 and the transforming growth factor-b (TGF-b) in GBM (Papagiannakopoulos 
et al., 2008; Schramedei et al., 2011; Samantarrai et al., 2013). WHO classifies brain 
tumours according to their morphology and metastasis amongst which most malignant 
form is Grade IV glioblastoma (GBM). Approximately 16 miRNAs were reported to be 
altered in GBM. The overexpression of miR-196a and miR-196b was reported in GBM 
(Guan et al., 2010). Various methods have been applied in order to determine miRNAs 
in malignant glioma, for example, 12 miRNAs were upregulated in glioma using stem-
loop RT-PCR while 55 were upregulated and 29 downregulated miRNAs were identified 
by LNA (Locked nucleic array) microarray (Guan et al., 2010; Malzkorn et al., 2010; Rao 
et al., 2010; Kim et al., 2010). miRNA expression profiles are reported to be more precise 
than mRNA profiling (Lu et al., 2005). Recently, the relationship between miRNA and 
mRNA was identified in glioblastoma (Srinivasan et al., 2011) and similar to other 
cancers, miRNAs in glioma are also associated with the hallmarks of cancer.  
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Figure 1.9: miRNAs interacting hallmarks of cancer miRNAs plays a crucial role in 
regulating cancer growth. They are known to interfere with the 10 hallmarks of cancer 
(Taken from Hanahan et al.,2011). 
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In glioma, cell proliferation is responsible for uncontrollable tumour growth which leads 
to disease progression. These involve cell cycle regulators such as CDK4 or CDKN2A that 
accelerate and promote glioma cell progression. For example, miR-137 stimulates cell 
proliferation by regulating CDK6 expression (Silber et al., 2008). Also, miRNAs regulates 
anti-apoptotic and pro-apoptotic molecules such as miR-181 and miR-153 targets BCL-2 
(b-cell lymphoma), an apoptotic protein in order to promote apoptosis and translation 
repression in glioma (Xu et al., 2010). The miRNA regulating molecular mechanism 
involves cell migration and invasion such as miR-21 and miR-30. They are associated with 
glioma angiogenesis, playing a role in Akt, VGFR and NF-kB pathways. They also 
contribute to cell development and maintenance in cancer stem cells. Radiotherapy and 
chemoresistance have always been obstacle for anti-cancer treatment. The membrane 
transporters resist drug induced apoptosis contributing to multi-drug resistance (MDR). 
miRNAs can also interacts with drug resistance molecules such as ATP-binding cassette 
(ABC) transporters (ABCG2/BCRP1, ABCB1/MDR1 and ABCA3), COX-2, Ras, Cyclin-D1, 
BCL-2 and Survivin (Liu et al.,2009; Lopez-Chavez et al.,2009; Bardelli et al., 2010). The 
miR-125b expression facilitates cancer cell resistance by blocking PI3K/Akt 
phosphorylation and caspase activation (Zhang et al., 2011; Shiiba et al., 2013).  
 miRNA Prediction tool 
Bioinformatic algorithms tools are crucial for identification of miRNA targets. These 
algorithmic pipelines assist in predicting miRNA targets computational with precision 
and sensitivity. These databases provide details of the similar seed sequence targets of 
miRNA along with its conserved sites. Databases such as miR2Disease, MirnaMAP, 
MiRecords, miRSel, miRTarBase, miRWalk, StarBase, TarBase 5.0, Diana microT, miRDB, 
Target miner, TargetscanVert are miRNA-mRNA predicting databases (Griffiths-Jones et 
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al., 2006; Griffiths-Jones et al., 2008) providing details of the miRNA validated or 
predicted target list accessed via these databases. 
miRNAs are highly conserved small non-coding RNA which played a crucial role in 
regulating functions. Various diseases have reported deregulation of miRNA. Thus, it is 
significant as it could be a biochemical tool for identification of biomarker for a disease. 
miRNA expression research analysis had diverse technical tool including Northern 
blotting, dot blotting, primer extension analysis, RT-qPCR, next generation sequencing 
(NSGs) and microarray (Nelson et al., 2006; Roy et al., 2011 ; Streichert et al., 2012). 
Among which, microarrays proved to be ideal for high throughput miRNA gene analysis 
as they were capable of simultaneously screening hundreds of target sequences within 
a single sample volume. They were appropriate for examining the relative expression 
between different biological samples. Thus, considering the advantages and cost-
effectiveness compared to other technologies, miRNA microarray profiling was used for 
the present studies (Qavi et al., 2010; Zhao et al., 2012). 
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1.5 Glioma biology 
Brain tumours which arise from different types of glial cells such as astrocytic, 
oligodendroglial and ependymal are collectively known as glioma (Appin et al., 2012, 
Wesseling et al., 2015). There are more than 130 types of brain tumours of which 
gliomas are most common primary brain tumours. The survival rate after diagnosis 
differs in age and gender. According to recent statistics in UK, 53% of diagnosed adults 
between ages of 15-39 have only five year survival time (Cancer Research UK, 2014). 
According to World Health Organisation (WHO), tumours are histologically 
characterized by their rate of proliferation, invasion, necrosis and angiogenesis. Grading 
of tumours are described below: 
Grade I: This is least malignant form of tumour with low proliferative rate and thus 
associated with long-term survival. Cell morphology is almost similar to non-cancerous 
cells. Surgical resection is effective treatment for this grade (Louis et al., 2007, Smoll et 
al., 2012). 
Grade II: Morphological appearance is slightly abnormal than non-cancerous cells. 
Despite of low proliferative rate they are known to recur as higher grade tumour after 
treatment indicating its infiltrative nature (Louis et al., 2007, Smoll et al., 2012). 
Grade III: Level of malignancy can be validated by abnormal morphology. They have 
comparatively high proliferative rate continuously reproducing abnormal cells. They are 
invasive in nature and often recur as higher grade tumour (Louis et al., 2007, Smoll et 
al., 2012). 
Grade IV: Most malignant form of tumour with high proliferation, invasive nature and 
mitotic activity. Due to its high proliferation rate, they tend to reproduce abnormal cells 
at higher rate and also cause high metastasis. Treating Grade IV is challenging due high 
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recurrence rate causing resistance to traditional treatment (Louis et al., 2007, Smoll et 
al., 2012). 
Examples of different grading includes Pilocytic astrocytoma (Grade I), astrocytoma 
(Grade II) forms low-grade tumours with only increased cellularity, anaplastic 
astrocytoma (Grade III) and Glioblastoma (GBM) (Grade IV) have evidence of endothelial 
proliferation and/ or tumour necrosis (Buckner et al., 2007). Every year more than 2,200 
cases are diagnosed with GBM which account for 55% of the malignant brain tumours 
(WHO grade I-IV) (Ohgaki & Kleihues, 2005, Cancer Research UK, 2014). GBM has 
extremely poor prognosis with median survival rate of 6 months (Cancer Research UK, 
2014). 
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1.6 Rationale for research  
 Working hypothesis 
Previous data have shown that HSP90α is highly expressed in glioma cell lines compared 
to normal astrocytes cells (Shervington et al., 2008; Cruickshanks et al., 2010). Thus, the 
HSP90 activity was targeted using 17-AAG, an HSP90 inhibitor. However, previous 
proteomics data showed that HSP70 was induced on inhibition of HSP90 (Munje et al., 
2011). Therefore, targeting HSP70 and HSP90 is imperative if glioma is to be tackled and 
overcome.  
Although tumour cells are responsive to TMZ treatment, its chemoresistance has been 
proven to be rather poor. However, a number of studies have been reported that involve 
overcoming resistance to Temozolomide. In the present study, a novel approach is being 
investigated involving targeting both HSP70 and HSP90 using inhibitory compounds. In 
order to understand the causes of tumour initiation and growth, it is important to 
acquire a more in-depth analysis of the underlying mechanism. The miRNAs are 
aberrantly active in normal cells but are extensively involved in tumourigenesis. Due to 
their unique ability to target multiple mRNAs simultaneously, their expression and 
regulation can provide an insight on the efficacy of the cancer treatment. The miRNA 
microarray technology is utilised to obtain gene expression and identify therapeutic 
biomarkers for the treatment of glioma (Stupp et al., 2005; Pearl et al., 2006; Yoshino et 
al., 2010).  
 Aim 
The aim of our research was to identify potential targets to improve efficacy of HSP70 
and HSP90 inhibitory drugs VER-155008 (VER) and 17-AAG, respectively comparing to 
Temozolomide (TMZ) as standard treatment. 
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 Specific Aim 
The main aim was to investigate HSP70 and HSP90 target in order to help treat glioma. 
1. To develop the technique of tissue culture using 1321N1, GOS-3 and U87-MG 
cells and using them for further studies. 
2. To undertake dose-dependent experiments to determine IC50 of TMZ, 17-AAG 
and VER-155008. 
3. To assess the gene and protein expression in Hsp70 and Hsp90α in glioblastoma 
cell lines before and after treatment with inhibitory drugs using qRT-PCR and 
ELISA. 
4. To determine the chemosensitivity using sequential and concurrent assay. 
5. To prepare cells for miRNA microarray experiment. 
6. Bioinformatic analysis of the miRNA microarray data. 
7. Integrated miRNA-mRNA analysis to validate microarray data. 
8. qRT-PCR validation using mRNA identified from integrated analysis. 
9. To analyse the data and write up the thesis. 
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 CHAPTER 2 
MATERIALS AND METHODS
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2.1 Materials 
Table 2.1: Reagents used for cell culture in this study. 
Reagents Abbreviation and Storage temperature Components Volume (ml) Suppliers 
Eagle’s minimum essential 
medium EMEM, 2-8°C 
2.0 g/l sodium bicarbonate, 4.5 g/l glucose, 10 mM 
hepes, 1.0 mM sodium pyruvate, 5.30 × 10-3 g/l phenol 
red 
 
500 Lonza, UK 
 
Dulbecco’s modified 
eagle’s medium DMEM, 2-8°C 
25 mM hepes, 1.0 g/l glucose, 1.0 mM sodium 
bicarbonate, 1.10 × 10-2 g/l phenol red 
 
500 Lonza, UK 
 
Foetal bovine serum FBS, -20°C Heat inactivated FBS (10%) 
 
50 GIBCO,UK 
L-glutamine -20°C 200 mM L- glutamine 
 
5 Sigma Aldrich, UK 
Non-essential amino acids 2-8°C 100× non-essential amino acid 
 
5 Sigma Aldrich, UK 
Essential amino acids 2-8°C  5  
Phosphate buffer saline 
(PBS,1×) PBS, 2-8°C 
8 g/l NaCl, 0.2 g/l KCl, 1.44 g/l,  Na2HPO4, 0.24 g/l 
KH2PO4, pH 7.4 
 
2 Fischer  Chemicals, UK 
Trypan blue (0.4%) Room temperature 0.81% sodium chloride, 0.06% potassium phosphate, dibasic 
 
_ Sigma Aldrich, UK 
 
Dimethyl sulfoxide DMSO, Room  temperature 
99.5% dimethyl sulfoxide, 
0.81% sodium chloride 
 
_ 
Sigma 
Aldrich, 
UK 
 
Sodium pyruvate (Na) 2-8°C Pyruvic Acid Sodium Salt 5 Lonza, UK 
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Table 2.2: A list of reagents and solutions used for agarose gel electrophoresis. 
Reagents Suppliers Preparation 
Working 
Concentration 
Ultrapure agarose 
Gibco BRL, 
UK 
0.6-2 g Agarose, 30-100 ml TAE (1×). Solubilised by boiling in a 
microwave for 3-4 min 
2% weight/volume 
10× TAE (Ultrapure 10× Tris Acetate EDTA 
electrophoresis buffer) 
Sigma, UK 
1 M Trizma base, 0.9 M Acetic acid (1×), 0.01 M EDTA Diluted 
to 1 x concentration with distilled water 
 
1× 
Gel loading dye 
 
Sigma, UK 
0.25% w/v Bromophenol blue, 0.25% w/v xylene cyanole, 40% 
w/v Sucrose. 
Supplied ready for use 4× concentration 
1:4 
Sample : dye 
Ethidium bromide 
10 mg/ tablet 
Amresco, 
UK 
 
10 mg Ethidium bromide in 10 ml distilled water. Diluted to 0.5 
μg/ml with distilled water 
1:20 
 
100 base pair (bp) molecular marker Sigma, UK 
100 μg supplied ready for use 
 
1 μg/ml 
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2.2 Methods 
2.3 Cell Culture 
 Cell lines 
The glioma cell lines U87-MG (Human glioblastoma astrocytoma grade IV), 1321N1 
(Human brain astrocytoma Grade II) and GOS-3 (grade II/III astrocytoma/ 
oligodendroglioma) were purchased from the European Collection of Cell Cultures 
(ECACC) and Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ), 
respectively were of human origin. Normal cell line NHA (Normal Human Astrocytes) 
was purchased from ECACC. All Cell lines (Table 2.3) were supplied in frozen ampoules 
in 1 ml plastic cryotubes in an appropriate freezing medium and were present in an 
appropriate freezing medium with 10% foetal bovine serum (FBS), 2 mM L-glutamine 
and 10% (v/v) dimethyl sulphoxide (DMSO). According to company recommendation, 
cells were grown in 75 cm2 or 25 cm2 tissue culture sterile polystyrene flasks (Sigma, UK) 
and maintained by incubating at 37 °C in a humidified 5% CO2 atmosphere. All cell lines 
were grown adherent as monolayer cultures.  
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Table 2.3: Cell line description and media formulation employed in this study. 
Cell lines Description WHO 
grade 
Culture Media Suppliers 
NHA Normal human astrocytes N/A  AGM™ BulletKit™ Lonza 
U87-MG Human brain glioblastoma-
astrocytoma epithelial-like cell line 
IV EMEM,  10% (v/v) FBS, 2 mM L-glutamine, 
1% (v/v) non-essential amino acid  and, 1 M 
Sodium Pyruvate  
 
ECACC, UK 
1321N1 Astrocytoma II DMEM, 10% (v/v) FBS, 2 mM  L-glutamine ECACC, UK 
GOS-3 Human brain mixed astrocytoma/ 
Oligodendroglioma 
II/III DMEM, 10% (v/v) FBS,  2 mM L-glutamine DSMZ, Germany 
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 Medium and reagents preparation 
The cell culture medium was made according to ECACC/ATCC/DSMZ recommendations 
by adding required supplements with suggested concentrations in sterile conditions 
(Table 2.1). Media were stored at 4˚C for 2-3 weeks within the stability period. 
Concentrations for preparation of supplements were calculated using below formula: 
V1 C1 = V2 C2 
𝑉𝑉1 =  𝑉𝑉1𝐶𝐶2𝐶𝐶1  
V1 =initial volume 
C1 = initial stock concentration 
V2 = final volume 
C2 = final concentration 
The above formula had been used for all calculations to determine the volume and 
concentration of the reagents and chemicals used in this study.
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 Resuscitation of the cells 
Each medium was pre-warmed at 37 °C in a water bath for approximately 30 min before 
thawing the frozen ampoules of cells. These ampoules were stored in liquid nitrogen 
and appropriate Personal Protective Equipment (PPE) was used. Following protocol of 
ECACC, ampoules of cell lines were partially opened in sterile conditions to release 
trapped nitrogen and then re-tightened. Cell lines were completely thawed at 37°C in a 
water bath for 1-2 min to minimise any damage to the cell membranes. Cells from 
cryotubes were resuspended in 2 ml of growth medium and centrifuged at 1000 rpm for 
5 min. The supernatant was discarded and the pellet was resuspended in fresh medium. 
After determining the appropriate volume to attain seeding density, cells were 
resuspended in labelled 25 cm2 flasks with the cell line name, passage number and date 
in a suitable volume of culture medium. Culture was mixed by shaking the flask 
backward and forward.  These flasks were then incubated at 37°C with 5% CO2 in filtered 
air and the medium was changed on alternate days. In order to maintain nutrient levels 
for slow growing cells, the medium was changed after every 48 h of incubation. Cells 
were observed under the light microscope with 10× magnification for monolayer growth 
of cells that were 70-80 % confluent after which they were sub-cultured. 
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 Subculture and cell library maintenance 
After obtaining appropriate confluence of cells, the cell culture medium was aspirated 
and the cells were washed using 2-3 ml of PBS. Thereafter, 1× trypsin was added to the 
cells by diluting in 2 ml of PBS and incubated at 37°C for approximately 3 min to remove 
cells that adhered to walls of flask. To ensure 95% cells detachment, the cells were 
observed under microscope. The medium with twice quantity of PBS (i.e. 4 ml) was 
added to flask to deactivate the effect of trypsin. Then, the media containing cells were 
transferred in a centrifuge tube and centrifuged at 1000 rpm for 5 min and cell pellet 
was obtained. Discarding supernatant media, cell pellet was resuspended in 1 ml of fresh 
media. 
 Quantification of cells using haemocytometer 
Cell suspension (20 µl) was aliquoted and quantified using a moistened 
haemocytometer. The cover slip was attached by applying pressure to create Newton 
refraction rings to ensure that the cover slip has affixed. The cell suspension was diluted 
by adding 0.4% Trypan blue to stain the dead cells for determining the total number of 
live cells. Cell suspension mix was pipetted at the edge of the cover slip and was allowed 
to run under the cover slip. Stained cells were visualised under a light microscope in the 
haemocytometer grid using 20× magnification (Figure 2.1). Only cells from the middle 
square were counted and quantified. Cells count was recorded and calculations were 
carried out to determine the cell concentration per ml of cell suspension following 
formula mentioned below:  
𝑋𝑋 = 𝑌𝑌 × 𝑑𝑑𝑑𝑑 ×  104cell/ml 
 [Y is cell count in grid square, df is dilution factor;  df = 20: z (z= total volume of 
Tryphan blue + total volume of cell suspension)]  
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Figure 2.1: Diagram showing haemocytometer grid under light microscope (Taken from 
PHE, 2013) 
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2.4 Cell Treatment with 17-AAG, VER and TMZ  
 Cell viability assay 
17-AAG (Invivogen, UK) and VER (Tocris Biosciences, UK) were dissolved in DMSO to 
provide a stock concentration of 2 mM. Temozolomide (TMZ) was dissolved in DMSO to 
make a stock concentration of 50 mM. To calculate the inhibitory concentration (IC50) of 
the drugs, the stock concentrations were further diluted in culture medium to achieve 
varying concentration of drugs. These were added to untreated cells and incubated for 
48 h in order to determine the IC50 and cell viability using all three cell lines. CellTiter-
Glo® Luminescent Cell Viability Assay determines the number of viable cells by 
quantifying ATP signals from presence of metabolically active cells (Crouch et al., 1993). 
Thus, cell viability was determined using CellTiter-Glo® Luminescent Cell Viability Assay 
(Promega, UK) according to the product protocol mentioned below:  
In white flat clear bottom 96-well plate 1 × 103 cells were seeded and incubated for 24 
h. The cells were treated with inhibitory concentration of the drugs (17-AAG, VER or 
TMZ) and further incubated for 48 h. Control well was prepared with only cell culture 
medium in order to obtain background luminescence value. A 96-well plate was 
equilibrated at room temperature for 30 min. Depending on the number of wells used, 
appropriate volumes of Cell Titer-Glo reagent was prepared by transferring the volume 
of Cell Titer-Glo buffer to the CellTiter-Glo substrate (1:1). The Content of the 96 well 
plates was emptied by pipetting. CellTiter-Glo reagent was diluted with the cell culture 
media and was added to appropriate wells. The 96-well plate was incubated on orbital 
shaker for 2 min in order to mix content and induce cell lysis. Thereafter, 96-well plate 
was then incubated at room temperature for 10 min, to stabilize luminescent signal. The 
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luminescent signal was detected using Tecan GENios Pro® (Tecan, Austria) at integration 
time of 0.25-1.00 second per well. 
 Chemosensitivity assay 
Chemosensitivity assay was carried out using two different methods. The concurrent 
assay, cells were treated with IC50 concentrations of three drugs individually and in 
combinations, following protocol under cell viability mentioned earlier. Luminescence 
signal was analysed and the treatment was compared to the standard treatment using 
TMZ while in sequential assay, cells were treated with 17-AAG or VER individually, 
followed by treatment of TMZ after 48 h. Then following above protocol reading were 
taken after 48 h. 
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2.5 Gene transcription technique 
 mRNA isolation 
Messenger RNA (mRNA) isolation was carried out using the mRNA isolation kit (Roche-
Diagnostics, Germany). This kit helped to directly isolate mRNA from cultured cells 
without intermediate of total RNA. The poly (A)+ tail of mRNA hybridized to a biotin-
labelled oligo (dT)20 probe. Using Streptavidin-coated magnetic particles biotinylated 
hybrids were captured and the magnetic particles were separated using a magnetic 
separator. The fluid was removed by washing with PBS buffer. Finally, the mRNA was 
isolated from the particles and incubated in redistilled water. Figure 2.2 below shows 
procedure for isolation of mRNA isolation and lists of the reagents and buffers used in 
this study (Table 2.4 and Table 2.5). This kit contains no aggressive reagent, thus it is safe 
and also has high purity. 
 
Figure 2.2: Experimental protocol for the mRNA isolation technique The poly (A)+ tail 
of mRNA hybridized to a biotin-labelled oligo (dT)20 probe and captured using 
streptavidin coated magnetic particles and these magnetic particles were removed  
using a magnetic separator. After the washes with PBS, mRNA was eluted and incubated 
in redistilled water. (Taken from mRNA isolation kit manual Roche Applied Sciences, UK 
2014).   
64 
 
 
Table 2.4: Reagents and buffers used for mRNA isolation (Roche applied sciences, UK) 
Reagents  Contents 
PBS Ice cold, pH 7.4 
Lysis Buffer 0.1 M Tris buffer, 0.3M LiCl, 10 mM EDTA, 1% lithium 
dodecylsulfate, 5mM DTT (dithiothreitol), pH 7.5 
Biotin-labelled 
Oligo(dT)20 probe 
100 pmol biotin-labeled  Oligo(dT)20 per µl of redistilled 
water 
Streptavidin 
Magnetic Particles 
(SMPs) 
Suspension of (10 mg/ml) in 50 nM Hepes, 0.1% bovine 
serum albumin, 0.1% chloracetamide, 0.01% 
methylisothiasolone, pH 7.4 
Washing Buffer 10 mM Tris buffer, 0.2 M LiCl and 1 mM EDTA, pH 7.5 
Redistilled Water 
(PCR Grade) 
RNAse free 
Storage buffer 10 mM Tris buffer, 0.1% chloracetamide, 0.01% 
methylisothiasolone, pH 7.5 
 
Table 2.5: Volumes of reagents and buffer used for mRNA isolation of 2 × 106 cells. 
Number of cells (2 × 106) Volume (µl) 
PBS 200 
Lysis buffer 500 
Biotin-labelled Oligo(dT)20 probe 0.5 
Volume of SMPs 50 
Lysis buffer (preparation of SMPs) 70 
Washing buffer 200 (× 3) 
Redistilled water 10 
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Experimental procedure:  
A total of 2 × 106 cells were pelleted to isolate mRNA. The Cells were washed twice using 
200 μl of ice cold PBS to remove excess medium. At the same time, magnetic particles 
were prepared and streptavidin magnetic particles (SMP) were thoroughly mixed. A 
volume of 50 μl of streptavidin magnetic particles were aliquoted into a sterile 
eppendorf tube. The streptavidin magnetic particles were separated from the storage 
buffer using the magnetic separator. Storage buffer was discarded. The magnetic 
particles were washed in 70 μl of lysis buffer and separated to remove the buffer. After 
washes, Lysis buffer (500 μl) was added to the cells and mechanically sheared six times 
using 21-gauge needle (1 ml). On 6th time of mechanical shearing with same needle. 
Sample was transferred to eppendorf tube containing magnetic particles in it. Biotin 
labelled oligo (dT)20 (0.5 μl) was added to sample and mixed to form the hybridization 
mix. It was then incubated at 37˚C in water bath for 5 min for immobilisation of the 
hybridisation mix. This hybridisation mix was incubated at room temperature on 
magnetic particle separator and the lysate was discarded. SMPs were washed three 
times with a 200 μl washing buffer. The eppendorf was place on magnetic separator 
each time to discard washing buffer. It was centrifuged for 1 min in order to removing 
remaining wash buffer. mRNA was eluted in 10 μl redistilled water and incubated at 65˚C 
for 2 min. Using the magnetic separator, the eluted mRNA was separated from the 
magnetic particles and transferred to labelled eppendorf tube and then stored at -20˚C. 
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 mRNA Quantification using NanoDrop spectrometer 
The Thermo scientific NanoDrop 1000 Spectrophotometer was used as it is fast and 
efficient for determining quantity and the purity of mRNA. It measured 1 μl samples with 
high accuracy and reproducibility which are highly concentrated samples without 
dilution. The Instrument operated by a patented sample retention technology that 
utilizes surface tension to hold the sample in place. This instrument helped to eliminate 
the use of cuvettes and also limits contamination since it is easy to clean. 
The instrument was controlled by a PC based software and the data were logged. After 
cleaning NanoDrop, application module settings were changed from Nucleic acid to RNA 
and a volume of 1 µl Distilled water was loaded on sampling arm with a fiber optic cable 
(the receiving fiber) and second fiber optic cable (the source fiber) was then brought 
into contact with the liquid sample causing the liquid to bridge the gap between the 
fiber optic ends.  A spectrophotometer utilized linear CCD (Charged Coupled-Device) 
array to analyse light passing through the liquid sample and this was set as a blank. The 
mRNA sample was loaded to measure and 260:280 (nm) value and ng/μl was recorded 
to check purity of mRNA. mRNA purity between 260:280 values must be in the range of 
1.5-2.00 which signified good purity. 
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  Complimentary DNA (cDNA) synthesis 
The First strand cDNA synthesis kit was used to reverse transcribe mRNA. This kit 
included AMV (Avian Myeloblastosis virus) enzymes isolated from Avian Myeloblastosis 
which synthesizes the new cDNA strand at the 3’-end of the poly (A)- mRNA where oligo 
dT was used as a primer. The quantity of mRNA sample used for cDNA synthesis varies 
according to purity of the mRNA obtained. From the concentration of mRNA obtained, 
the required concentration for 100 ng was determined. The quantity of 100 ng was to 
maintain as a constant quantity for preparation of all samples. 
The Protocol of Roche applied sciences was followed to synthesis first strand cDNA. All 
reagents and samples were thawed at room temperature while the RNase inhibitor and 
AMV reverse transcriptase were thawed on ice and vortexed. In order to avoid 
contamination, all equipments used were autoclaved. The master mix of 11.8 µl was 
prepared using reagents provided in first cDNA synthesis kit (Roche applied sciences, 
UK) (Table 2.6). The quantified amount of mRNA (100 ng) was added, followed by the 
addition of sterile water to attain a final volume of 20 μl in each sample and the mixture 
was briefly vortexed and centrifuged. 
Mastermix was first incubated at 25°C for 10 min for the primer to anneal to the mRNA 
template. During the second incubation at 42°C for 60 min, mRNA was reverse 
transcribed to cDNA and following incubation at 99°C for 5 min, AMV Reverse 
Transcriptase denatured on incubation. Sample was then cooled to 4°C for 5 min and 
stored at −20°C.  
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Table 2.6: Reagents used in first strand cDNA synthesis for one sample. 
Reagents Volume of reagents 
(µl) 
Final concentration 
10× Reaction buffer 2.0 1× 
25 mM Magnesium chloride 
(MgCl2) 
4.0 5 mM 
Primer Oligo-p(dT)15 2.0 0.04 A260 units (0.06 
µɡ) 
RNAse inhibitor 1.0 50 units 
AMV-Reverse Transcriptase 0.8 ≥20 units 
Deoxynucleotide mix 2.0 1 mM 
Total volume 11.8  
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 Gene sequence and Primer design 
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) is used as housekeeping gene 
while Hsp70 (Hspa8 from Heat shock protein 70 kDa family also known as HSC70) and 
Hsp90a (Heat shock protein 90 kDa) are targeted genes which are constitutively 
expressed. Using GeneCards database, gene locations were determined. The mRNA 
sequence of each gene was obtained using NCBI database. In order to carry out a study 
of genes using polymerase chain reaction (PCR), requires a primer to amplify the gene. 
This primer was designed using Primer3Plus software analysing obtained mRNA 
sequence. As described in Figure 2.3 -Figure 2.11. 
 GAPDH 
 
Figure 2.3: Gene location of GAPDH, a housekeeping gene using GeneCards database. 
Red bar represents location of GAPDH gene. 
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 Figure 2.4: mRNA sequence of GAPDH gene & the locations of the primers using NCBI 
database. Primer locations have been highlighted in blues and yellow indicating sense 
and antisense primers, respectively.  
 
Figure 2.5: Primer design of GAPDH gene using Primer3Plus. The output page of 
Primer3 provides the right and the left primers. 
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 Hsp70 
 
Figure 2.6: Gene location of Hspa8 (Hsp70) using GeneCards. Red bar represents 
location of Hsp70 gene. 
 
Figure 2.7: mRNA sequence of Hspa8 (Hsp70) & the locations of the primers using NCBI 
database. Primer locations have been highlighted in blues and yellow indicating sense 
and antisense primers, respectively. 
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 Figure 2.8: Primer design of Hspa8 (Hsp70) using Primer3Plus. The output page of 
Primer3 provides the right and the left primers. 
 Hsp90 
 
Figure 2.9: Gene location of Hsp90a (Hsp90) gene using GeneCards database. Red bar 
represents location of Hsp90 gene. 
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 Figure 2.10: Gene location of Hsp90a (Hsp90) gene & the locations of the primers using 
GeneCards database. Primer locations have been highlighted in blues and yellow 
indicating sense and antisense primers, respectively. 
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 Figure 2.11: Primer design of Hsp90a (Hsp90) using Primer3Plus. The output page of 
Primer3 provides the right and the left primers. 
 
 
 Primer preparation 
Primers were synthesised by TIB MOLBIOL (Berlin, Germany). Each primer (right/sense 
and left/antisense) was dissolved in 250 μl of molecular biology grade water to obtain 
20 μM stock solutions and stored at -20°C as recommended by the manufacturer. 
Annealing temperature of Primers were used using manufacturers recommendations as 
mentioned in Table 2.7.   
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Table 2.7: Primer sequence, annealing temperatures and amplicon size for GAPDH, Hsp90α and Hsp70 primers used in qRT-PCR. 
Gene Primer sequence Annealing Temperature (°C) Amplicon size (base pair (bp)) 
GAPDH 
Sense: 5’ – gagtcaacggatttggtcgt – 3’ 
Antisense: 5’ – ttgattttggagggatctcg – 3’ 
56 238 
Hsp70 
Sense: 5’ – ggaggtggcacttttgatgt  – 3’ 
Antisense: 5’ – agcagtacggaggcgtctta – 3’ 
60 198 
Hsp90a 
Sense: 5’ – tctggaagatccccagacac – 3’ 
Antisense: 5’ – agtcatccctcagccagaga – 3’ 
63 189 
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 Quantitative real time polymerase chain reaction (qRT-PCR) 
qRT-PCR is a technique enabling consistent detection and quantification of products 
generated during each cycle of the PCR process. It logarithmically amplified short DNA 
sequences (usually 100-600 bases) within a longer double stranded DNA molecule. Thus, 
it enabled detection of very low copies of the target-specific product amplification 
(Roche Applied Science, UK).  Hsp90a, Hsp70 and GAPDH were amplified by performing 
qRT-PCR on the LightCycler 2.0 system (Roche Diagnostics, Germany). The experiments 
were carried out using LightCycler® FastStart DNA Master PLUS SYBR Green I kit 
following the manufacturer’s instructions. LightCycler reaction Master Mix was 
prepared by using the reagents from the kit provided that includes 1a (white cap) 
Lightcycler FastStart Enzyme and 1b (Green Cap) Lightcycler FastStart DNA MasterPLUS 
Reaction Mix. A volume of 14 µl of 1a was pipetted into 1b. The 1b was re-labelled as 1 
which represents the Mastermix. Mastermix was stored at 4°C and protected from light. 
The reagents and samples were thawed and kept on ice throughout the experiment. PCR 
enzyme mastermix was made from components of the LightCycler® FastStart DNA 
Master PLUS SYBR Green I kit (Table 2.8) with the recommended volume for each 
sample. PCR mastermix was briefly centrifuged. Capillaries were placed on the capillary 
adapter and 2µl PCR grade H2O was loaded as a negative control and 2 µl cDNA sample 
in the other capillaries. Capillaries were centrifuged for a minute and then transferred 
to LightCycler sample carousel and then into the LightCycler instrument. 
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Table 2.8: Components required for LightCycler® FastStart DNA Master PLUS SYBR 
Green I kit sample preparation for qRT-PCR primer mastermix. 
Components Volume (µl) 
Molecular biology H2O, PCR grade 12 
PCR Primer mix (Left +  Right Primer) 2  (1 µl + 1µl) 
PCR enzyme master mix 4 
cDNA template 2 
 
Following the settings found in Table 2.9, qRT-PCR run was carried out. This protocol 
involved several steps which played an important role. Pre-incubation, FastStart DNA 
polymerase was activated and DNA was denatured. This also increased PCR specificity 
and sensitivity by preventing non-specific elongations. Target DNA was amplified and 
melting provides melting curves for analysis of the PCR product. The final step involved 
cooling of the rotor and the thermal chamber where PCR product is placed.  
Table 2.9: LightCycler program for qRT-PCR utilizing Fast Start DNA MasterPLUS SYBR 
Green Kit. 
Analysis 
mode 
Cycles Segments Target temperature (°C) 
Hold time 
(sec) 
Pre-
incubation 
1  95  
 
Amplification 
35 
Denaturation 95 15 
Annealing 
Variable to (refer table 
primers) 
15 
Extension 72 9 
 
Melting 
1 
Denaturation 95 0 
Annealing 10 higher than amplification 15 
Extension 95 0 
Cooling 1  40 30 
78 
 
 Analysis of RT-PCR amplicons using agarose gel electrophoresis 
Gene expression was determined by running PCR products of cDNA samples on 2% 
agarose gel electrophoresis (AGE). Agarose (0.8 g) was dissolved in 40 ml of 1× TAE 
buffer to obtain 2% agarose gel. This solution was heated in a domestic microwave at 
700 W power for 2 min until agarose particles were thoroughly dissolved. The solution 
was then poured into casting tray set with comb and cooled for 45 min to set gel. The 
comb was removed after solidified of the agarose gel and was placed into 
electrophoresis gel tank. 1× TAE running buffer (300 ml) was poured into gel tank until 
the level to cover the gel (Table 2.2). The loading sample contained 2 μl of loading dye 
and 5 μl of PCR products sample amplicons. A volume of 5 μl of 100 bp molecular marker 
was loaded along with samples to determine the molecular weight as standard at 50 V 
for approximately 1 h. The gel was stained with 0.5 µg/ml of Ethidium bromide (EtBr) 
for 30 min, followed by destaining in water for 20 min. The bandings patterns were 
observed using a GENE GENIUS Bioimaging system, UK and Gensnap software (Syngene, 
UK).  
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 Copy Number Quantification 
Copy number standard curve (Figure 2.12) was generated to calculate the copy numbers 
of the unknown samples (Hsp70, Hsp90a and GAPDH) by plotting the crossing point or 
Ct value against copy numbers. This standard curve was previously established in our 
laboratory (Shervington et al., 2007). 
 The external standard of known concentration or copy number was used to accurately 
determine amount of target amplicon. Previous experiments have established the 
quantification of copy numbers from the crossing point by using genomic DNA as a 
template (Shervington et al., 2007). A standard curve was plotted for the quantitative 
method established on the Light Cycler® 2.0 Real-Time PCR (Mohammed et al., 2008). A 
standard genomic DNA (QIAGEN, UK) with known concentration of 1 μg equivalent of 
3.4 × 105 copies of a single gene was prepared using five concentrations (5 pg, 50 pg, 
500 pg, 5 ng and 50 ng, Table 2.10). Further amplification was achieved by the 
LightCycler® using GAPDH reference gene with its threshold cycle (Ct) numbers in order 
to plot the standard curve. The equation generated (y = -1.3124Ln(x) + 32.058) from the 
standard graph was rearranged to (=EXP {Ct value-32.058)/-1.3124}) to determine the 
copy numbers of the mRNA expression of all the genes used throughout the study. 
Table 2.10: Genomic DNA correspondence to its average Ct values and equivalent 
copy number. 
Genomic DNA concentration (ng) Dilution factor Average Crossing point (Ct) 
50 17000 18.3 
5 1700 22.6 
0.5 170 26.42 
0.05 17 29.12 
0.005 1.7 30.15 
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(a) 
 
(b) 
 
Figure 2.12: Standard to calculate the copy number of the targeted gene. (a) Light 
Cycler quantification curve generated with known concentration of genomic DNA 
amplified, showing that the higher the concentration of DNA the lower the Ct values. 
The negative control (Primer alone) shows no fluorescence acquisition until after 30 Ct 
(straight line). (b) The standard generated from the crossing points showing the 
relationship between Ct values and the copy numbers of the amplified genomic DNA 
using GAPDH as a reference gene (n=3) (Taken from Mohammed et al., 2008).  
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 Protein extraction and quantitation 
Bradford reagent is quick, efficient and sensitive which utilises Coomassie blue dye. This 
dye appeared to be red-brown in an acidic solution but when binds to protein due to a 
shift in dissociation constant, it changes to blue colour. This dye was measured at 595 
nm. Thus, the absorbance reading obtained was directly proportional to amount of dye 
bound to protein enabling the determination of the concentration of protein in the 
sample. In order to determine unknown concentrations of protein in samples, a 
standard curve was plotted with increasing concentration of bovine serum albumin 
(BSA) ranging from 1-8 µg/µl prepared in PBS (1×). BSA was used and recommended 
since it shows negligible interference in absorbance readings. 
Protocol was carried out as follows: 
Cell Pellets were thawed and centrifuged at 1200 rpm for 5 min at 4°C to obtain the cell 
pellet and the supernatant was discarded. Cells were washed with 500 µl of ice cold PBS. 
According to the amount of cell pellet, cells were resuspended in Celytic M cell lysis 
reagent (Sigma, UK). For 1 × 106 Cells, a volume of 50 µl of Cell lysis reagent was added 
while for less than 1 × 106 Cells, 30 µl of cell lysis reagent was added. On cell lysis, the 
release of proteases could lead to degradation of protein. Thus, 1 µl of protease inhibitor 
was added to prevent degradation. Further, samples were incubated at room 
temperature on a shaker for 15 min. Followed by centrifugation at 13000 rpm for 5 min 
at 4°C. The supernatant was collected in a fresh tube (supernatant contains protein). 
The protein concentration was measured using the Bradford protein assay method. The 
protein quantitation was carried out using Coomassie blue reagent (1 ml CBR + 9 ml 
distilled H2O) at 595 nm. CBR and sample (1:1000) was aliquoted into cuvettes and 
incubated for 2 mins. The absorbance was measured at 595 nm using gamma thermo 
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Helios spectrophotometer (Thermospectronics, UK). A standard curve was plotted and 
the concentration of the unknown protein was extrapolated Figure 2.13. Each protein 
was assayed at least 2 times and the mean values taken.  
 
Figure 2.13: Protein quantitation standard curve. The equation was used to calculate 
the concentration of protein in test samples. The values shown are mean ± SD, n = 3.  
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 Akt/PKB kinase assay  
Akt/PKB kinase activity kit was designed for analysis of PKB (Protein Kinase B) activity in 
the solution; based on solid phase enzyme linked immune-absorbent assay (ELISA). It 
utilised a synthetic peptide as substrate for PKB accompanied by a polyclonal antibody 
to recognise phosphorylated forms of substrate. The Akt Kinase activity kit is a safe, 
rapid and a reliable technique.  
The components of kit that included PKB substrate microtitre plate, Antibody dilution 
buffer, Kinase assay dilution buffer, TMB substrate and Stop solution 2 were equilibrated 
at room temperature before use and the reagents were prepared according to 
manufacturer’s instructions. Required number of wells from the PKB substrate 
microtitre plate was soaked with 50 μl of Kinase assay dilution buffer at room 
temperature for 10 min. After aspirating the liquid from each well, varying concentration 
of active PKB (2.5, 5, 10, 20 and 40 ng) were added to the appropriate wells in microtitre 
plate. Except for the blank, 10 μl of diluted ATP was added to each well in order to 
initiate the reaction. The plate was then incubated at 30°C in an orbital shaker at 60 rpm 
for 60 min. The reaction was stopped by emptying the content of the well. Except for 
the blank, 40 μl of phosphospecific substrate antibody was added to each well and then 
incubated for 60 min. at room temperature. All the wells were washed four times with 
100 μl of 1× wash buffer considering 2 min interval for each wash. Except for the blank, 
40 μl of diluted Anti-Rabbit IgG: HRP Conjugate was added to each well. After incubating 
the plate at room temperature for 30 min, the wells were washed four times with 100 
μl 1× wash buffer. Each well was then treated with 60 μl of TMB substrate. The plates 
were incubated at room temperature. According to the development of the colour, 
incubation time was determined between 10-15 min. In a similar order to that of the 
TMB substrate, 20 µl of the stop solution 2 was added. The absorbance was then 
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measured at 450 nm using a microtitre plate reader.  A standard curve was then plotted 
(Figure 2.14). 
 
 
Figure 2.14: Standard curve for Akt kinase activity assay obtained using purified 
recombinant active Akt The provided recombinant active Akt was diluted in Kinase 
Assay Dilution Buffer to give final concentration from 5-40 ng/assay. The equation 
derived from the curve was then used to calculate the Akt activity in treated and 
untreated samples based on the absorbance readings. This graph is typical of three 
independent experiments. Data values are mean ± SD, n = 3. 
  
y = 0.0393x + 0.2779
R² = 0.9539
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
0 5 10 15 20 25 30 35 40 45
Ab
so
rb
an
ce
 a
t 4
50
 n
m
Active Akt concentration (ng/assay)
Standard curve for Akt Kinase activity
85 
 
 Assay Procedure 
Protein sample (1 µg) was calculated using protein standard curve and diluted in kinase 
buffer to obtain volume of 30 µl. The assay procedure performed was similar to the 
standard curve procedure but with a few modifications. At step 3, after aspirating the 
liquid from each well, the sample volume was added to the appropriate wells in the 
microtitre plate. After reading absorbance at 450 nm. Values were further analysed and 
the kinase activity was determined by using the standard curve of PKB kinase. A similar 
protocol was followed for both the untreated and drug-treated cells. The working 
principle is explained in Figure 2.15. 
 
Figure 2.15: Schematic representation of Akt/PKB kinase activity kit mechanism 
Adapted from instruction manual (adapted from Enzo life sciences, UK).  
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2.6 miRNA microarray profiling 
 
Figure 2.16: Schematic diagram representing workflow for miRNA microarray 
experiment. 
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 Drug treatment for miRNA microarray analysis 
U87-MG cells were seeded in 75 cm2 flasks 48 h prior to treatment. Cells were treated 
with IC50 of drugs (TMZ, 17-AAG or VER). After 48 h, cells were harvested for miRNA 
microarray analysis and stored in RNA protect Cell reagent (Qiagen, UK) at -80°C. The 
cells samples were shipped on dry ice for analysis. miRNA microarray analysis was 
carried out by IMGM laboratories.  
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 miRNA microarray analysis 
 Isolation of total RNA including small RNAs 
miRNeasy Mini kit utilised phenol/guanidine for sample lysis and silica membrane–
based technique of purification of total RNA. QIAzol lysis reagent provided in the kit had 
monophasic solution, Phenol/guanidine thiocyanate which lysis cell/tissue by inhibiting 
RNases and helped in extracting Total RNA without traces of cellular DNA and proteins 
from the extracted lysate. In order to isolate Total RNA, Cell sample pellets were 
collected by centrifugation at 5,000×g for 20 min. in order to remove supernatant 
RNAprotect Cell Reagent and total RNA including the small RNA fractions was isolated 
using the miRNeasy Mini Kit (Qiagen) mentioned below (Figure 2.17). 
 
Figure 2.17: Schematic representation of isolation of total RNA (Adapted from Qiagen 
miRNeasy protocol). 
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QIAzol lysis Reagent (700 µl) was added to the cell pellet and pellet was loosen by flicking 
and then vortexing for 1 min. in order to avoid inefficient lysis of cells and homogenising. 
(for ≤ 3 × 106 cells). The sample was placed at RT for 2-3 min. in order to promote 
dissociation of nucleoprotein complexes. This homogenate containing tube was 
vigorously shaken after addition of Chloroform (140 µl) to ensure thorough mixing 
followed by incubation at RT for 2-3 mins. The sample was centrifuged for 15 min. at 
12,000× g at 4°C which separated samples into 3 phases: upper colourless phase 
containing RNA, whiter Phase and lower red organic phase. The upper aqueous phase 
was transferred to new collection tube provided in the kit. Followed by addition of 1.5 
volumes of 100% ethanol and thorough mixing. (Followed next step immediately 
without any delay as addition of ethanol may form precipitate). A volume of 700 µl of 
the sample was pipetted including any formed precipitate into an RNeasy Mini spin 
column in a 2 ml collection tube. Samples were centrifuges at 8,000× g (10,000 rpm) for 
15 s at RT (15-25 °C). Flow through containing QIAzol lysis reagent was discarded. Repeat 
above step using remainder sample and discarded the flow through. 
Followed by On-column DNA digestion for >1 μg total RNA approximately as described. 
A volume of 350 µl of Buffer RWT was pipetted into the RNeasy Mini Spin column and 
centrifuge 15s at 8,000× g (10,000 rpm) to wash and discard flow through. DNAse I stock 
solution 10 µl was added to 70 µl Buffer RDD and mixed gently by inverting. DNase I 
incubation mix (80 µl) was pipetted directly onto the RNeasy Mini spin column 
membrane and incubated for 15 min at RT (20-30°C). Complete DNase mix was loaded 
on membrane by avoiding residue sticking to walls or o-ring of the RNeasy mini spin 
column. A volume of 350 µl Buffer RWT was pipetted into the RNeasy Mini Spin column 
and centrifuge 15s at 8,000× g (10,000 rpm) to wash and discard flow through.  A volume 
of 350 µl buffer RPE was pipetted onto RNeasy Mini spin column and centrifuged 15s at 
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8,000× g (10,000 rpm) to wash and discard flow through. This was followed by addition 
of 500 µl Buffer RPE to the RNeasy Mini spin column and centrifuged 15s at 8,000× g 
(10,000 rpm) drying spin column membrane ensuring no ethanol carried over.  RNeasy 
spin column was transferred onto new 1.5 ml collection tube and RNase-free water (30 
µl) added directly on the spin column membrane. The lid was closed gently and 
centrifuged for 1 min at 8,000× g (10,000 rpm) and total RNA was eluted. 
 Determination of RNA concentration and purity 
The concentration and Purity of RNA was determined by using NanoDrop ND-1000 
spectral-photometer (peqLab). The working of spectrometer was mentioned earlier in 
section mRNA quantification. Total RNA samples with A260/A280 ratio of > 1.6 indicated 
absence of contaminating proteins while A260/A230 ratio of > 1.0 indicated the absence 
of other organic compounds such as guanidinium isothiocynate, alcohol and phenol also 
other cellular contaminants. 
 RNA integrity control 
The Agilent 2100 bioanalyzer is a device utilised to monitor total RNA samples quality 
using capillary electrophoresis prior to performing labelling reaction for microarray 
analysis. The Bioanalyzer is a microfluidic electrophoretic device that separated RNA 
according to fragment size and produces an electropherogram used to assess RNA 
degradation and RNA quantity. It calculated RNA integrity number (RIN) allowed user to 
easily assess the quality of their RNA samples. RIN scale ranges from 1 to 10, where 1 
denoted massive RNA degradation and 10 denoted excellent RNA quality. RIN measured 
sample integrity and this was determined by ribosomal-RNA ratio 28s /18s r-RNA along 
with entire electrophoretic profile including the presence or absence of degradation 
products (Figure 2.18). According to recommendations of Agilent technologies, All 
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samples were analysed using RNA Nano LabChip Kit and also, only Total RNA samples 
with RIN values ≥ 7.5 were used for labelling reaction in order to achieve high quality 
cRNA and evaluable microarray results. 
 
Figure 2.18: Typical electropherograms representing eukaryotic total RNA degradation 
analysed on 2100 Bioanalyzer (a) intact RNA (b) Partially degraded RNA (c) Degraded 
RNA (Adapted from Schroeder et al., 2006). 
 Preparation of Cyanine-3 labeled miRNA 
The Total RNA samples were spiked using microRNA Spike-In kit (Product no.: 5188-
5282), Agilent Technologies to serve as an internal labelling control to measure labelling 
and hybridisation efficiency. 100 ng Total RNA samples were then introduced to ligation-
based reaction where samples were treated with Calf Intestinal Alkaline Phosphatase 
(CIP) and the dephosphorylated RNA were labelled using T4 RNA Ligase which involved 
ligation of one Cynanine 3-pCp molecule to the 3’ end of a RNA molecule (miRNA 
Complete Labelling and Hyb kit, Agilent Technologies).  
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 Microarray hybridization  
This procedure was followed by preparation of One-Color based hybridisation of the 
Cyanine 1-pCp-labelled miRNA sample. Samples were hybridised at 55°C for 20 h. on 
separate Agilent Human miRNA Microarrays Release 19.0 in 8×60K format (AMADID 
046064). Microarrays were washed with increasing stringency using Triton X-102 
supplemented Gene Expression Wash Buffers (Agilent Technologies) followed by drying 
with acetonitrile (SIGMA). Fluorescent signal intensities were detected with Scan 
Control A.8.4.1. Software (Agilent Technologies) on the Agilent DNA microarray scanner 
and extracted from the images using Feature Extraction 10.7.3.1 software (Agilent 
Technologies) and the design file 046064_D_F_20121223.xml. This part of the work was 
carried out by IMGM laboratories in Germany. 
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 Bioinformatics data analysis 
This study used software tools Feature Extraction 10.7.3.1, GeneSPring GX 12.5 (Agilent 
Technologies) and Sportfire Decision Site 9.1.2 (TIBCO) for quality control, statistical 
data analysis, miRNA annotation and visualization.  
Quantile data normalization was applied to the data set in order to impose the same 
distribution of probe signal intensities for each array. It maintained median values and 
intensity distribution of all arrays by shifting all intensities at uniform levels enabling 
comparison of microarray for downstream analysis. The data was visualised as log2 
transformed manner (after normalization) or as raw data (before normalization). 
The similarity between the samples were detected using correlation analysis. Pearson’s 
correlation coefficients (r) were calculated for all biological replicates within the groups 
and for all pairwise comparisons of the samples in the experiment and correlation 
coefficient heat map were produced. 
Further, raw data was produced by calculating average with replicated sample log2 
transformed data. Three pairwise sample comparisons were analysed. U87-MG 
untreated cells were used as reference group and gene expression of U87-MG TMZ-
treated, U87-MG 17-AAG-treated and U87-MG VER-treated, respectively, was 
compared to the reference group (U87-MG untreated Control).  
 Statistical analysis of microarray data 
Welch’s approximate Student’s t-test was applied to the comparison of these different 
groups which produces a p-value (p). Benjamini and Hochberg False Discovery Rate 
(FDR) adjustment algorithm was applied to avoid multiple testing errors which could 
usually occur when there is more number of standard probes compared to analysed 
samples and corrected p value was determined. Sample groups were then compared in 
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pair-wise manner in order to achieve differential expression between the groups by 
calculating fold change (FC). The ratio of raw values between the groups was calculated.  
Using Feature Extraction 10.7.3.1 software robust differentially expressed probes were 
detected which screens only probes which are reliably detectable in at least one out of 
all samples of the two compared groups. Following these statistical analyses, data sets 
was further filtered by applying different stringency levels:  
a) Stringent filtering in which a probe was only classified as induced or repressed if its 
corrected p-value (corrected) is ≤ 0.05 and its Fold change (FC) is ≤ (+/-) 2 
b) Non-stringent filtering in which a probe is only classifies as induced or repressed if its 
non-corrected p-value (non-corrected) is ≤ 0.05 and its Fold change (FC) is ≤ (+/-) 2. The 
multiple testing errors were not taken into consideration while applying Non-stringent 
filtering. 
 miRNA Target prediction 
The experimental identification and validation of miRNAs regulatory site was a challenge 
due to its multi targeting ability of miRNA. Thus, various different pipelines or algorithms 
were developed in order to predict its mRNA targets. Moreover, they had specific 
working principle. The main method of prediction of miRNA targets implied 
identification by perfect or imperfect complementarity by Watson-Crick base pairing 
between miRNA and possible mRNA target. Some utilised perfect pairing in the seed 
sequence while other also considers evolutionary conservation of the miRNA target. 
Also, the prediction of target was done by identifying binding energies between 
imperfect base pairing. There were few other factors by which is utilised by algorithms 
for prediction of miRNA targets. Currently, an online repository for miRNA is maintained 
by University of Manchester (www.mirbase.org) developed by Sanger Institute. This 
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database provided details of miRNAs along with validated and predicted algorithm links 
which mainly included Target Scan Human 6.2, DIANA-microT and miRBD miRBase V18. 
As mentioned earlier, each algorithm predicted miRNA target utilising different method. 
Thus, in order to reduce false target, this study considered miRNA targets with high 
conserved sites and miRNA target which were validated or co-predicted by two or more 
algorithms. Further, Intersection analysis was carried out by overlapping with down 
regulated and up regulated data set (Park et al., 2013). Further, Predicted mRNA targets 
were validated using qRT-PCR. Following the primer design (Table 2.11), qRT-PCR and 
statistical analysis procedure carried out as mention earlier in this chapter. 
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Table 2.11: Primer sequence, annealing temperatures and amplicon size for selected primers used in qRT-PCR. 
Gene Primer sequence Annealing temperature (°C) Amplicon size (base pair) 
Dnmt3a 
Sense 5’–ccggaacattgaggacatct–3’,  
Antisense 5’–cagcagatggtgcagtagga–3’ 
56 162 
Alcam 
Sense:  5’–cgtctgctcttctgcctctt–3’ 
Antisense: 5’–taaatactggggagccatcg–3’ 
56 175 
Cdk4 
Sense 5’–gaaactctgaagccgaccag–3’,  
Antisense 5’– aggcagagattcgcttgtgt–3’ 
56 213 
Dnajc16 (Hsp40) 
Sense 5’– ctcccaaagtgctgggatta–3’, 
Antisense: 5’–agagcttttgggctgaaaca–3’ 
54 196 
R-Ras2 
Sense 5’–agcacggcagcttaaggtaa–3’, 
Antisense: 5’–tggcagcctttcttgtcttt–3’ 
54 165 
97 
 
2.7 Preparation of cell lysate 
The cells were treated with respective drugs and approximately 1 × 106 cells were 
harvested for measuring activity of HSP70 and HSP90. Cell pellets were thawed and 
centrifuged at 1200 rpm for 5 min at 4°C to obtain the cell pellet and the supernatant 
was discarded. Cells were washed with 500 µl of ice cold PBS. According to the amount 
cell pellet, cells were resuspended in 1× Extraction reagent was added (For 1 × 106 Cells 
1 × 107 Cells = 1 ml Extraction reagent). Extraction regent helped homogenisation of 
cells. Also, in order to avoid protein degradation, a volume of 1 µl Protease inhibitor 
cocktail was added to 1× Extraction reagent. Suspension was incubated on ice for 30 min 
with occasional mixing. This was followed by centrifuge at 21,000× g for 10 min at 4°C. 
The supernatant (Cell lysate) was transferred into new labelled polypropylene tubes 
without disturbing pellet. 
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 HSP90α ELISA kit 
HSP90α ELISA kit is a quantitative sandwich immunoassay used to determine HSP90α 
concentration in cell lysates of human origin. It utilised HSP90α specific mouse 
monoclonal antibody pre-coated on the wells to capture HSP90α in the sample or 
standard which was detected using an HSP90α antibody conjugated with horseradish 
peroxidase (HRP). Quantity of HSP90α was detected by measuring colour using 
microtitre plate reader at 450nm developed by TMB substrate and acidic stop solution 
which developed endpoint colour.  
According to manufacturer’s protocol, the reagents of the kit was thawed and brought 
to room temperature (Anti-HSP90α immunoassay plate, 20× wash buffer, sample 
diluent, HRP conjugate diluent, TMB substrate and Stop Solution 2). The recombinant 
HSP90α standard (0.0625 – 4 ng ml) and samples (500 ng/mL total protein) were 
prepared in sample diluent making up total volume 250 µl. Thereafter, standards and 
samples (100 µl) were added to the wells of Anti-HSP90α immunoassay plate and 
incubated at room temperature for 60 min. Zero standard (sample diluent only) was 
added as blank or reference. This was followed by washes (6 times) with 1× wash buffer 
and pat dry each time. Then, diluted HRP conjugate (100 µl) was added to the wells 
except blank and incubated for 60 min. Again repeating washes (6 times) with 1× wash 
buffer. Followed by addition of TMB substrate to each well and further incubate for 20 
min at room temperature. Followed by addition of Stop Solution 2 to each well following 
same order as TMB substrate was added. Absorbance was measured at 450 nm. 
Standard curve was plotted and concentration of HSP90α in each samples was 
determined using the standard plot equation (Figure 2.19). 
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 Figure 2.19: HSP90α activity standard curve Active recombinant HSP90α standard was 
diluted in Kinase Assay Dilution Buffer to give final concentration from 0.0625 - 4 
ng/assay. The equation derived from the curve was then used to calculate the HSP90α 
activity in treated and untreated samples based on the absorbance readings. This graph 
is typical of two independent experiments. Data values are mean ± SD, n = 4. 
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 HSP70 ELISA kit 
HSP70 ELISA kit is a quantitative sandwich immunoassay. Immunoassay plate was pre-
coated with HSP70 specific mouse monoclonal antibody which was detected by the 
HSP70 specific rabbit polyclonal antibody. These HSP70 specific antibody were further 
bound by a horseradish peroxidase conjugated anti-rabbit IgG secondary antibody. The 
concentration of HSP70 was measured by measuring intensity produced by TMB 
substrate at endpoint after adding Stop solution 2. The intensity of colour developed 
was directly proportional to concentration of HSP70 present in the standards and 
samples. 
According to manufacturer’s protocol, the following reagents were brought to room 
temperature: Anti-HSP70 Immunoassay Plate (required number of wells), Sample 
Diluent 2, Wash Buffer, HSP70 Antibody HSP70 Conjugate, TMB Substrate, and Stop 
Solution 2. Recombinant HSP70 Standards and samples were prepared using Sample 
diluent. Standards and Samples (100 µl each) were added in duplicates to the wells of 
Anti-HSP70 Immunoassay Plate. Zero standard (0 ng/mL) with sample diluent was 
added. Plate was covered and incubated at room temperature for 2 h. Wells were 
washed 4 times using 1× wash buffer and Pat dried each time. Plate was covered and 
incubated for 1 h at room temperature after addition of HSP70 Antibody (100 µl) except 
blank. Followed by washes (4 times) using 1× wash buffer and Pat dried each time. 
Except Blank, HSP70 Conjugated 100 µl was added to all the wells and incubated at room 
temperature for 1 h. Repeating wash procedure (4 times). Wells were pat dried. TMB 
substrate (100 µl) was added to each well and incubated at room temperature for 30 
min. Stop solution (100 µl) was added to each well after 30 min to stop reaction and 
absorbance was measured using Tecan Microplate reader at 450nm. Standard curve of 
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HSP70 concentration was plotted and HSP70 concentration of Samples was calculated 
using the equation obtained by HSP70 standard curve (Figure 2.20). 
 
Figure 2.20: HSP70 activity standard curve The active recombinant HSP70 standard was 
diluted in Kinase Assay Dilution Buffer to give final concentration from 0.78-50 ng/assay. 
The equation derived from the curve was then used to calculate the HSP70 activity in 
treated and untreated samples based on the absorbance readings. This graph is typical 
of two independent experiments. Data values are mean ± SD, n = 4. 
 
2.8 Statistical analysis 
The data were analysed using SPSS package and Graph pad Prism for One-Sample 
Student’s T-test and Paired-Sample T-test. A value of *p < 0.05 and **p < 0.001 was 
taken as significant. 
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CHAPTER 3  
RESULTS 
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3.1 Cell culture growth curves 
Error! Reference source not found. shows time course of growth curves for 1321N1, GOS-3 and U87-MG glioma cell lines. The results show that all 
three cell lines grow in similar manner over the period of six days. However, U87-MG were used for further analysis involving drug treatments. Cells 
were used after four days of culture.  
 
Figure 3.1: Growth curves of glioma cell lines used in this study The values shown are mean ±SD, n = 3 (*p=0.05). 
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3.2 mRNA isolation and qRT-PCR 
mRNA purity was determined by analysing the absorbance ratio at 260: 280 on mRNA 
isolation using NanoDrop spectrophotometer. mRNA concentrations used for cDNA 
synthesis are in Table 3.1. 
Table 3.1: mRNA purity using Nanodrop spectrometer and mRNA concentration used 
for cDNA synthesis. Data are mean ±SD, n = 3. 
Cell Lines Ratio (A260/A280) mRNA concentrations (ng/µl) 
1321N1 1.89 ± 0.03 35.5 ± 3.2 
GOS-3 1.92 ± 0.02 62.5 ± 5.4 
U87-MG 2.05 ±0.02 60.3 ± 4.3 
NHA 1.99 ± 0.1 52.3 ± 3.6 
 
The volume of mRNA (100 ng) was calculated for cDNA synthesis. GAPDH, Hsp70 and 
Hsp90α gene transcription was measured using Real time PCR. The data shows that 
Hsp70 and Hsp90α levels were significantly induced in glioma cell lines (*p < 0.05), while 
Hsp70 was absent. Similarly, Hsp90α was transcribed at basal levels in the normal cell 
line. Thus, there was no reason to use normal astrocyte cell line for further study.   
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Figure 3.2: Bar chart showing the gene expressions of Hsp70 and Hsp90α in glioma cell 
lines mRNA copy number of Hsp70 and Hsp90α in glioma cell line and normal cell lines 
has been shown. *p < 0.05 was considered statistically significant. Data values are mean 
± SD, n = 3. The data show graphical representation of elevation of Hsp70 and Hsp90 in 
glioma cell lines compared to control cell line (NHA). 
106 
 
3.3 Inhibitory concentration (IC50) of TMZ, 17-AAG and VER in glioma 
cell lines 
The 50% Inhibitory concentrations of Temozolomide, 17-AAG and VER for 48 h were 
determined on each of the three glioma cell lines. The cells were treated with increasing 
concentrations of the inhibitory compounds and the cell viability was analysed using 
CellTiter-Glo® Luminescent cell viability assay. Previously, cell viability using non-
cancerous glioma cell line was established using HSP inhibitory drug (Mehta et al., 2011). 
Thereby, NHA was excluded for this experiment. Figure 3.3-Figure 3.5 below show 
decreased glioma cell viability with increases in the drugs dose. The 50% inhibition 
concentrations (IC50) for glioma cell lines are listed in Table 3.2. 
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 Figure 3.3: Dose-dependent inhibitory effects on cell viability employing different concentrations (µM) of Temozolomide. The drug was assessed by 
increasing concentrations of TMZ on 1321N1, GOS-3 cell line, U87-MG cell line.The data values are mean ± SD, n = 3. 
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 Figure 3.4: Dose-dependent inhibitory effects on cell viability employing different 
concentrations (0 – 500 nM) of 17-AAG. The Hsp90 inhibitor was assessed by increasing 
concentrations of 17-AAG on (A) 1321N1, (B) GOS-3 and (C) U87-MG. The data values 
are mean ± SD, n = 3. 
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 Figure 3.5: Dose-dependent inhibitory effects on cell viability employing different 
concentrations (µM) of VER. The Hsp70 inhibitor was assessed by increasing 
concentrations of VER on (A) 1321N1 cell line (0.0-16.0 µM), (B) GOS-3 cell line (5.5-10.0 
µM) and (C) U87-MG cell line (9.0-18.0 µM). The data values are mean ± SD, n = 3. 
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Table 3.2: The IC50 concentrations of chemotherapeutic drug TMZ and Hsp inhibitory 
drugs 17-AAG & VER on the three different cancer cell line. The values are mean, n = 3. 
Cell lines 17-AAG (nM) VER (µM) Temozolomide (µM) 
1321N1 100 12.3 135 
GOS-3 100 12 147 
U87-MG 80 13 180 
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3.4 Akt activity in glioma cell lines 
Akt kinase plays a major biochemical role as a client protein to HSP70-HSP90 complex. 
Akt stabilises HSP90 and activates HSP70/90 complex through phosphorylation which 
leads to activation of signalling proteins involved in cell survival. Thus, the presence of 
HSP70 and HSP90 can be determined by increased levels of Akt/PKB levels. The Akt/PKB 
levels in glioma cell lines were measured using established method. The Akt activity in 
glioma cell lines treated with TMZ, 17-AAG and VER was assessed in order to examine 
the effect of each inhibitory drug on the Akt/PKB kinase activity levels. 
The protein was extracted from drug-treated and untreated samples of 1321N1, GOS-3 
and U87-MG and quantified using a standard curve (Figure 2.13). The determined 
quantity of protein was used to measure protein Akt levels. Akt activity level was 
obtained (Table 3.3) by extrapolating experimental absorbance values on standard curve 
equation obtained from standard curve graph (Figure 2.14). These data showed 
correlation with the gene expression data of Hsp70 and Hsp90α.  
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Table 3.3: Determination of Akt kinase activity (ng/assay). *p < 0.05 was considered 
statistically significant. Data values are mean ± SD, n=3. 
Cell lines Treatment Kinase activity for ng/assay 
NHA Untreated 43 ± 2 
1321N1 
Untreated 84 ± 37 
TMZ 22  ± 3* 
17-AAG 7 ± 3* 
VER 52 ± 4* 
GOS-3 
Untreated 201 ± 7 
TMZ 69 ± 4* 
17-AAG 82 ± 6* 
VER 156 ± 5* 
U87-MG 
Untreated 121 ±15 
TMZ 17 ± 3* 
17-AAG 32 ± 5* 
VER 20 ± 2* 
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3.5 Chemosensitivity assay with 17-AAG and VER in the glioma cell lines 
Chemosensitivity assay was carried out on the three glioma cell lines in two different 
ways, using both Concurrent assay and Sequential assay. In the concurrent assays, cells 
were exposed to 17-AAG, VER and TMZ in different combination or alone followed by 
incubation for 48 h (Figure 3.6). In sequential assays, cells were exposed to 17-AAG, VER 
and TMZ alone for 24 h followed by treatment with TMZ. The cells were further 
incubated for 48 h (Figure 3.7). 
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 Figure 3.6: Bar charts showing concurrent chemosensitivity assay using glioma cell lines. The data showed that cell viability was significantly reduced 
in combinational treatment for 48 h where three cell lines were examined for treatment along with TMZ. *p < 0.05 and **p < 0.001 were considered 
statistically significant (Data values are mean ± SD, n = 3). 
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 Figure 3.7: Bar charts showing sequential chemosensitivity assay using glioma cell lines. The data showed that cell viability was significantly reduced 
in combinational treatment where three cell lines were treated with TMZ, 17-AAG and VER. After 24 h, 17-AAG and VER treated cells was exposed to 
TMZ followed by incubation of 48 h. *p < 0.05 and **p < 0.001 were considered statistically significant (Data values are n = 3, mean ± SD).  
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3.6 Analysis of miRNA regulation 
Earlier data have confirmed elevated HSP70 and HSP90α activity in glioma cells as mRNA 
expression profiles and Akt kinase activity in the three glioma cell lines. These initial data 
have established importance of Heat shock proteins based on chemosensitivity assay 
results. Thus, U87-MG cell line was used for further analysis. miRNAs are commonly 
dysregulated in human malignancies and they possess the ability regulate thousands of 
mRNA simultaneously (Lu et al.,  2005). Thus, in order to understand therapeutic effects 
of drug at molecular level and to further determine potential molecular targets, miRNA 
microarray was carried out. Further in the research, U87-MG cells were treated with IC50 
of TMZ (Standard treatment) and heat shock protein inhibitory compounds, 17-AAG and 
VER, respectively for 48 h (Table 3.2). miRNA expression profiling was performed on 8 
samples (includes 3 treated samples and a untreated as control). Samples were analysed 
on Agilent Human miRNA Microarrays Release 19.0 (8×60K format). All the procedures 
were carried out according to manufacturer’s protocol. 
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 Total RNA concentration, purity and integrity  
Total RNA was extracted from the samples and concentrations and A269/A280 ratios of 
each sample was determined by spectral photometry on the NanoDrop ND-1000 
instrument. RNA integrity was assessed on the Agilent 2100 Bioanalyzer. The results are 
shown in Table 3.4. The results show that RNA concentrations of all samples were found 
to be sufficient for microarray analysis and their purity (as indicated by the A260/A280 
and A260/A230 ratios) was found to be very good. All total RNA samples were found to 
have RIN (RNA Integrity Number) values above 9.4, indicating excellent RNA quality. The 
electropherogram of all analysed samples along with electrophoretic gels are also 
shown in Figure 3.8 and Figure 3.9. All samples were used for miRNA microarray analysis. 
Table 3.4: Table showing quality control results for the total RNA samples using U87-
MG. (Data values are mean ±SEM, n=2) 
Treatment Sample 
Concentration 
(ng/µl) 
A260/A280 
ratio 
A260/A230 
ratio 
RIN 
U87-MG 
Untreated 
Control 1 560.8 2.04 1.76 9.7 
Control 2 513.9 2.06 1.53 9.8 
U87-MG 
Treated 
TMZ 1 568.6 2.06 2.25 9.7 
TMZ 2 540.3 2.08 2.25 9.8 
17-AAG 1 658.8 2.08 2.24 9.7 
17-AAG 2 695.5 2.07 1.94 9.6 
VER 1 126.8 2.04 1.97 9.4 
VER 2 106.4 2.07 2.18 9.6 
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Figure 3.8: Original electrophoresis gel for assessing RNA integrity. L represents marker 
ladder and lane 1-8 represents total RNA samples used for miRNA microarray (1) U87-
MG Control-Set 1 (2) U87-MG Control-Set 2 (3) U87-MG TMZ-Set 1 (4) U87-MG TMZ-Set 
2 (5) U87-MG 17-AAG-Set 1 (6) U87-MG 17-AAG-Set 2 (7) U87-MG VER-Set 1 (8) U87-
MG VER-Set 2. (A) 18s (B) 24s. (Correlating with Figure 3.9).  
 
  
119 
 
  
 
 
 
Figure 3.9: Original chart recordings showing electropherogram for RNA integrity. Each 
graph recording  produced by Bioanalyzer represents total RNA samples used for miRNA 
microarray (A) U87-MG Control-Set 1 (B) U87-MG Control-Set 2 (C) U87-MG TMZ-Set 1 
(D) U87-MG TMZ-Set 2 (E) U87-MG 17-AAG-Set 1 (F) U87-MG 17-AAG-Set 2 (G) U87-MG 
VER-Set 1 (H) U87-MG VER-Set 2.  
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 Microarray analysis  
Each array was analysed using Feature extraction software. All criteria of Feature 
extraction quality analysis was fulfilled. The Additive Errors was in below 12 for each 
array as recommended by one-Color-based hybridization (Agilent). Analysis of Spike-In 
signals demonstrated equal and good performance of each single labelling and 
hybridisation experiment. Hyb Spike-in Signal obtained in between range of 4.49 – 4.57 
which is above recommended threshold of 2.50 for all arrays.  
 Quantile normalization of microarray data 
Quantile normalization is commonly used for nonlinear normalization which adjusts all 
microarray samples to similar data distribution. It helps to eliminate intensity 
differences within microarrays and ensure that differential data obtained. The box plot 
in Figure 3.10 demonstrates the effects of quantile normalization for all analysed 
samples (Bolstad et al., 2003). Box plots are usually representation of normalised 
distribution of data. In Figure 3.10, 50% of the data are within boxes and blue horizontal 
line represents median of the data. The red part above the box plot whiskers represents 
outliners. Box plot obtained in the study is different than the standard plot. This may be 
due to low overall signal intensities and low or weakly expressed miRNA data sets within 
each samples. 
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 Figure 3.10: BoxWhisker plot after quantile normalization. (Data values are mean 
±SEM, n=2) 
 Correlation analysis 
In order to determine degree of relationship within and between the samples, Pearson’s 
correlation coefficient was analysed. The heat map of correlation coefficient shown in  
Figure 3.11 represents the correlation coefficient from obtained values within biological 
samples and also, between the different experimental groups. The data shows that r 
within biological samples shows high level of correlation ranging from 0.982 to 0.995 
and r between experimental group such as control and TMZ, control and 17-AAG, 
control and VER shows average correlation ranging from 0.954 to 0.975.  
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Figure 3.11: Heat-Map plot for correlation coefficients (r). Demonstrating correlation 
between and within the experimental samples. The colour range start at a low level of 
r=0.950 (green) and ends at the highest level of r= 1.000 (red). Red represents high 
correlation. Data values are mean ±SEM, n=2. 
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Each microarray was analysed for quality control using standardised set of QC metrics 
to ensure samples can be accounted for bioinformatic analysis. The filtered flag 
information was applied on each array to obtain ‘Detected’ (D) and ‘Not Detected’ (ND) 
data. In Table 3.5, % Detected is mentioned for each sample array. 2,027 systemic names 
were found to be ‘Detected’ in each sample.  
Table 3.5: Data showing detected systemic names on application of filtered flag 
information. Data values are mean ±SEM, n=2. 
Samples % Detected 
U87_Control S1 25.4  
U87_Control S2 22.9  
U87_TMZ S1 24.5  
U87_TMZ S1 25.4 
U87_17-AAG S1 24.9  
U87_17-AAG S2 24.6  
U87_VER S1 28.0  
U87_VER S2 27.8 
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 Differential miRNA expression  
Following % detected samples, the data were filtered to obtain quantile normalisation 
and log2 transformed data were averaged within biological replicates. The pair-wise 
comparison was carried out using U87-MG-Control as reference group and gene 
expression of U87-TMZ, U87-17-AAG and U87-VER were compared to the reference 
group. Different filtering approaches were carried out for identification of differentially 
expressed miRNAs in the pair-wise comparisons. Statistical analysis included application 
of both FDR (False Discovery Rate)-corrected p-value (p (Corr) and the non-corrected p-
value (p), respectively, in combination with a Fold change ≥ │2│. Initially, 2074 systemic 
names in each sample and on applying stringent approach on pair-wise comparison, 13 
differentially expressed miRNAs were obtained which are expressed in VER Vs control 
(See Table 3.6). There are no miRNAs expressed on stringent filter on comparison with 
TMZ and 17-AAG. Table 3.6 also shows non-stringent filtering data which have high a 
number of miRNAs, but these miRNAs have less reliability as they are not FDR-corrected 
p-value-based filtering.  
Table 3.6: Table showing the summary of differentially expressed miRNAs.  
Comparison 
p(Corr) ≤ 0.05 │FC│ ≥ 2 p ≤ 0.05 │FC│ ≥ 2 
Up Down Up  Down 
TMZ Vs Control 0 0 19 7 
17-AAG Vs Control 0 0 4 1 
VER  Vs Control 9 4 61 62 
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 Analysis of significantly regulated miRNAs 
Differentially expressed miRNAs were further evaluated for determining overlapping of 
expressed miRNAs in different groups from both stringent and non-stringent data sets 
(Table 3.7). A total of 12 upregulated miRNA was present in both TMZ Vs control and 
VER Vs control. Among the upregulated miRNAs, hsa-miR-194-5p, hsa-miR-215, hsa-
miR-449a, hsa-miR-744-5p and has-miR-3161 showed higher fold change difference 
while there was only one downregulated hsa-miR-4636 with lower fold difference.  
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Table 3.7: Significantly regulated miRNAs with overlapping of expressed miRNAs. (FC-
Fold change,  represents p(corrected) miRNAs). Data values are mean ±SEM, n=2 
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 miRNA target genes 
Further details about each miRNA was obtained using the miRBase: The miRNA database 
(http://www.mirbase.org). Each miRNA description was filtered for cancer relevant 
miRNAs. These database also provide details of validated experiments on predicted 
targets. Based on the differentially expressed miRNAs Table 3.7, further targets were 
determined using different target predicting algorithm such as Target Scan Human 6.2, 
DIANA-microT and miRBD miRBase V18. These algorithms predict mRNA targets 
according to the complementarity of the miRNA seed. As each algorithm utilises 
different method for determination, therefore, in order to avoid false targeting, mRNA 
targets which are confirmed by two or more algorithms were taken into account. 
According to functions, publication or novel gene relevant for this study, was 
determined. miRNA related to cancer progression was used for quantification of 
expression (Table 3.8). 
Table 3.8: Table showing the predicted gene using gene target algorithms 
miRNA Treatment Regulation Predicted gene target 
hsa-miR-194-5p TMZ & VER Upregulated Dnmt3a 
hsa-miR-215 TMZ & VER Upregulated Alcam 
hsa-miR-449a TMZ & VER Upregulated Cdk4 
hsa-miR-744-5p TMZ & VER Upregulated Dnajc16 (hsp40) 
hsa-miR-3161 17-AAG & VER Upregulated R-Ras2 
128 
 
 Validation of selective gene expression 
In Table 3.9 and Figure 3.12, gene expression levels of selected gene were monitored to 
examine treatment efficiency in U87-MG cell lines. 
 Table 3.9: Table showing the validation of gene expression analysis of selected genes. 
(Data values are mean ±SEM, n=3, *P<0.05 compared to control). 
 Control TMZ 17-AAG VER 
Dnmt3a 2 ± 0 2 ± 0 2 ± 0 25 ± 6 
Alcam 33 ± 5 4253 ± 603 477 ± 100 84 ± 1* 
Dnajc16 (hsp40) 293 ± 41 30976 ± 281 5102 ± 370 1455 ± 119 
Cdk4 160 ± 15 1359 ± 203 482 ± 21* 561 ± 31* 
R-Ras2 51 ± 6 214 ± 41* 357 ± 28* 441 ± 77* 
Hsp70 442 ± 129 129 ± 16* 192 ± 8* 43334 ± 847 
Hsp90 829 ± 145 373 ± 71* 1484 ± 362 91863 ± 877 
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 Figure 3.12: Bar charts showing Gene transcription levels of selected genes. (Data values are mean ±SEM, n=3; *p<0.05for test compared to control 
for each set)
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3.7 HSP70 and HSP90 activity  
HSP70 and HSP90 are predominantly expressed heat shock proteins and they found to 
be elevated in glioma (See Table 3.10 and Table 3.11). In this study, VER and 17-AAG 
have been used as HSP70 and HSP90 inhibitory drugs, respectively. Therefore, validated 
variation is confirmed in protein expression after treatment of inhibitory compounds 
using HSP70 and HSP90 activity ELISA kit.  
Standard curves were plotted to determine HSP70 and HSP90 activities in treated and 
untreated samples using recombinant HSP70 and HSP90. The equation in each graph 
was utilised to calculate the HSP70 and HSP90 activity levels in the samples (Figure 2.19 
and Figure 2.20). In order to determine effects of Hsp-specific inhibitory treatment and 
validate gene transcription data investigation was carried out using U87-MG cell lysate 
of total protein 0.5 µg.   
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Table 3.10: Table showing HSP70 activity in U87-MG cell lines. (Data values are mean 
± SD, n=3, *p<0.05 compared to untreated) 
Samples HSP70 activity for 0.5 µg protein 
U87-MG Untreated 77 ± 11 
U87-MG TMZ 67 ± 17* 
U87-MG 17-AAG 81 ± 9* 
U87-MG VER 62 ± 6* 
 
Table 3.11: Table showing HSP90 activity in U87-MG cell lines. (Data values are mean 
± SD, n=3, *p<0.05 compared to untreated) 
Samples HSP90 activity for 0.5 µg protein 
U87-MG Untreated 558 ± 62 
U87-MG TMZ 92 ± 12* 
U87-MG 17-AAG 322 ± 36* 
U87-MG VER 198 ± 16* 
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 CHAPTER 4  
DISCUSSION 
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Heat shock proteins are molecular chaperones that function to facilitate protein folding 
and they regulate cellular activity in both normal and diseased conditions (Sreedhar et 
al., 2004). Particularly, in cancers, heat shock proteins are key mediators in regulating 
cell survival and, they are known to interfere in pathways leading to apoptosis. In this 
way, they encourage cell division and cell proliferation. HSP70 and HSP90 together with 
client proteins form a mature complex in order to maintain proliferation, progression of 
cell cycle and apoptosis. Heat shock proteins are also involved in invasion, angiogenesis 
and metastasis. 
Therefore, targeting both HSP90 and HSP70 can be an effective approach in the 
treatment of cancer. The expression of both HSP70 and HSP90 have been reported in 
malignant tumours such as breast cancer, prostate cancer and cervical cancer (Fawzy et 
al., 2013). Both HSP70 and HSP90 families have different isoforms which play major roles 
in various locations in the cellular environment, of which HSP70 and HSP90α are known 
to be the most inducible forms (Bisht et al., 2003). Therefore, this research focuses on 
the expressions HSP70 and HSP90α in glioma cells.  
Glioma cell lines (1321N1, GOS-3 and U87-MG) were cultured in the lab using 
appropriate and safe techniques. Cell growth curve data shows that under normal 
conditions, 1321N1 and GOS-3 cell lines attain doubling time after 48hrs while U87-MG 
doubling time was after 72hrs. Cell growth curves validated cell viability or density at a 
given time, the subculture frequency and the phase of cell growth. Therefore, cell 
growth was restricted to 70-80 % confluence to avoid external stress (Assanga et al., 
2013). The results obtained after studying the expression of heat shock proteins have 
clearly demonstrated the presence of Hsp70 and Hsp90α in glioma cell lines and their 
relative absence in normal cell lines. Previous studies in our laboratory have reported 
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the expression of Hsp90α gene and protein in glioma cell lines (Shervington et al., 2008; 
Mehta et al., 2011). Quantitative analysis of transcription levels of Hsp90α and Hsp70 
gene was assessed using qRT-PCR. GAPDH (Glyceraldehyde 3-phosphate 
dehydrogenase) was used as housekeeping gene since it is stable and constitutively 
expressed at high levels. The mRNA copy number has shown an overexpression of 
HSP90α and HSP70 in glioma cell lines compared to NHA (normal human cell lines). 
HSP70 belongs to the heat shock protein 70 family which plays key roles in stabilising 
HSP90 by acting as major co-chaperone to HSP90. Together, they maintain a stable 
cellular environment and carry out the main function of chaperoning misfolded proteins.  
Similar to HSP90, HSP70 is also present at minimal levels in unstressed cells but under 
stress like conditions, the number of misfolded proteins rises, therefore increasing the 
need for heat shock proteins. In stress-like conditions, this leads to the overexpression 
of HSP70 and HSP90α. HSC70 (Heat shock cognate protein 70) is expressed at basal 
levels while HSP70, which is the more inducible form, is overexpressed in cancers. Heat 
shock Factor-1 (HSF-1), is known as a transcription factor which binds to both HSP70 and 
HSP90 in the inactive state. HSP70 and HSP90 dissociate from HSF-1 and subsequently, 
they are phosphorylated by regulatory protein kinases, bound to heat shock element 
(HSE) on the promoter region of Hsp90 leading to the over expression of Hsp gene. Even 
though HSP90 inhibition is a highly efficient cellular mechanism, its effect is overcome 
by triggering Heat Shock Response (HSR) and elevated levels of HSP70 to compensate 
for the activity of HSP90α, ultimately leading to increased chemoresistance. PCR 
transcription data have shown that Hsp70 and Hsp90a are highly expressed in glioma 
cell lines and almost undetected in normal cell lines. Also, cell viability or toxicity of HSP 
inhibitors was previously measured on non-cancerous cell lines (Mehta et al., 2011). 
Thus, NHA (normal cell line) was not included in further investigations. The 
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transcriptional activity level of Hsp90α was higher than Hsp70 in glioma cell lines 
1321N1, GOS-3 and U87-MG. Proteomic analysis data have shown that the inhibition of 
HSP90 can lead to the upregulation of HSP70. HSP70 is a potential target for treatment 
of glioma (Munje et al., 2011; McConnell et al., 2013). The present investigation focused 
mainly on the inhibition of the upregulated HSP70 and HSP90α, whereby dual targeting 
for both HSP70 and HSP90 were investigated using inhibitory drugs. 
Benzoquinone ansamycin antibiotics which are known to be HSP90 inhibitors have the 
ability to inhibit multiple targets by specific binding to HSP90 N-terminal pocket. These 
include 17-allylamino-17-demethoxygeldanamycin (17-AAG), first geldanamycin 
analogue to enter clinical trials (Goetz et al., 2003). In the current study, 17-AAG was 
found to decrease glioma (U87-MG) cell viability at a dosage of 80 nM (IC50 
concentration) after 48 h of incubation. 17-AAG appears to be effective at low levels due 
to its high affinity for the binding pocket in HSP90. It shows similar affinity in other 
cancer cells, such as breast cancer cell lines (Workman et al., 2004).  In addition to 17-
AAG as an HSP90 inhibitory compound, this study also investigated VER-155008 (VER), 
an HSP70 inhibitor. The inhibitory concentration (IC50) of VER using U87-MG cell line 
over a 48 h period treatment was determined to be 13 µM. This concentration was used 
in all the experiments investigating the effect of VER. Similar IC50 values for VER have 
been previously reported in colon cancer cell lines (HCT16, HT29) and breast cancer cell 
lines (BT474, MDA-MB-468) (Massey et al., 2010). The inhibitory concentrations of 17-
AAG and VER were also determined using 1321N1 and GOS-3 cell lines. The IC50 of 17-
AAG for 1321N1 cell and GOS-3 cell lines was 100 nm. The IC50 of VER was found to be 
12 µM for 1321N1 and GOS-3 cells lines. The IC50 demonstrates the efficacy of both drugs 
with all three cell lines. 17-AAG inhibits HSP90 activity by blocking ATPase binding pocket 
on N-terminal and is also proved as less toxic in vivo (Xia et al., 2012). VER targets HSP70 
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with high affinity at lower concentrations and also it targets other members of HSP70 
family (HSC70 and GRP78) and HSP90β at lower affinity (Massey et al., 2010). 
HSP90 has an array of client proteins regulating cell survival pathways and other signal 
transduction or apoptosis pathways (Goetz et al., 2003). Some of these client proteins 
behave as oncoproteins. These client proteins include extracellular signal-regulated 
kinase (ERK) 1, GLUT-1, HER-2, Camp-dependent protein kinase, RAF-1, Akt and vascular 
endothelial growth factor (VEGF) expression (Picard et al., 2002). Akt is one of these 
client proteins that stabilises HSP90/70 multi-protein complex and it functions as a key 
modulator in apoptotic pathways. The active form of Akt is also stabilised by this 
intracellular complex with HSP90 along with CDC37 (client protein). The active Akt 
phosphorylates proapoptotic proteins such as BAD and transcription factors that 
suppress apoptotic activities. Therefore, Akt/PKB kinase assay was carried out to 
determine levels of Akt/PKB which directly helps to determine levels of HSP90 and 
HSP70 before and after treatment with inhibitory drugs (Basso et al., 2002; Zhang et al., 
2012a). 
The Akt/PKB kinase activity assay data confirmed previous findings showing increased 
Akt kinase activity in glioma cell lines compared to normal cell lines (Mehta et al., 2011). 
The significant increase in Akt activity in glioma cell lines have shown dependence on 
HSP70/90 complex stability. In 1321N1 cells, Akt activity with TMZ, 17-AAG and VER 
treated cells was reduced by 26, 8 and 62 %, respectively. In GOS-3 cells treated with 
TMZ, 17-AAG and VER showed reduced activity by 34, 41 and 78 %, respectively, while 
U87-MG cells have showed a reduction of 14, 26 and 17 %, respectively. In all three cell 
lines, Akt kinase activity was reduced on treatment with the inhibitory compounds. 
Theoretically, inhibition of HSP90 leads to disrupt interaction of Akt with the HSP90 
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complex. It also maintains unstable Akt and prevents formation of active Akt which 
interacts with other proapoptotic proteins in the apoptosis pathway, thereby, 
suppressing cell proliferation and regulating apoptosis of malignant cells. Therefore, 
mRNA quantification and Akt kinase activity data have shown reduced Akt kinase activity 
on treatment with inhibitory compounds which was consistent with previous studies 
(Mehta et al., 2011). Therefore, the overexpression of HSP70/90 in cancer cell lines has 
emerged as molecular target (Zhang et al., 2012b). 
In this study, Temozolomide (TMZ) was used as standard anti-cancer treatment. The 
inhibitory concentration of Temozolomide was determined and the IC50 values obtained 
were 135, 147 and 180 µM for the 1321N1, GOS-3 and U87-MG cell lines, respectively. 
With the concurrent assay, the cells were treated with all three drugs individually or in 
combination. For the sequential assay, the cell lines were treated separately with either 
17-AAG, VER or TMZ and then incubated for a period of 48 h. In addition, the cell lines 
were treated either with 17-AAG or VER for 24 h, followed by TMZ for an additional 24 
h. In the combination treatment using TMZ with 17-AAG and VER with 1321N1, showed 
cell viability reduced to 23 and 34 %, respectively, after 48 h. In addition, the 
combination treatment of TMZ with 17-AAG and VER using GOS-3 exhibited cell viability 
reduced to 17 and 31 %, respectively, after 48 h. In the concurrent assay using U87-MG 
cells, combination treatment of TMZ with 17-AAG and VER showed cell viability reduced 
to 43 and 32 %, respectively, after 48 h.  Therefore, concurrent treatment using 1321N1, 
GOS-3 and U87-MG cells confirmed effectiveness of combinational treatment compared 
to the drugs treated individually. In all cell lines, the combination treatment using TMZ 
and VER was found to be the most significant, reducing 32%. Sequential assays have 
shown similar effects for combination treatment after 72 h. This reinforced that the use 
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of combinational treatment, enhances cell chemosensitivity towards standard 
treatment of TMZ. 
This study has demonstrated the over-expression of Hsp70 and Hsp90α in glioma cell 
lines by gene transcriptional analysis and Akt/PKB kinase activity. Chemosensitivity 
enhancement was monitored against standard treatment of Temozolomide using 
sequential and concurrent methods using 1321N1, GOS-3 and U87-MG cell lines. The 
most effective treatment was found to be with the U87-MG cell line. Interestingly, the 
activity of the inhibitory drugs was found to be significantly higher in the concurrent 
method. Therefore, transcriptional activity and kinase activity with combinations of the 
drugs was validated so as to establish the therapeutic importance and U87-MG cell line 
was used for the scheduled studies. The data demonstrated effectivity of treatment 
using U87-MG was most significant. Therefore, U87-MG was treated with the 
established IC50 of 17-AAG, VER and TMZ. 
Recently, miRNAs have highlighted their importance as a novel class of tumour 
suppressor or oncogenic role. Dysregulation of miRNAs has been reported in various 
diseases. miR-21, for instance, is known as an anti-apoptotic miRNA linked to 
tumourigenesis. More than 2000 human miRNAs have been identified which makes it 
feasible to apply microarrays enabling miRNA expression analysis in large numbers of 
samples (Miska et al., 2004). miRNA microarrays have been useful in the classification 
of various cancers by defining miRNA markers predicting potential biomarkers (Esquela-
Kerscher et al., 2006; Caramuta et al., 2013). Dysregulated miRNAs have been reported 
in glioma (Skalsky et al., 2011). miRNA expression or function may be altered due to 
genetic mutations, epigenetic silencing and chromatin modifications (Cullen et al., 
2008). Most importantly, these non-protein coding single stranded RNA molecules 
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regulate post-transcriptional gene expression. Understanding molecular mechanism of 
anti-cancer drugs is essential for determining efficient drug responses (Cullen et al., 
2008, Skalsky et al., 2011). 
The cancer genome project was carried out involving a large panel of cancer cell lines 
which were screened by almost 138 drugs and contributed to the identification of 
mutated genes (Garnett et al., 2012; Bateman et al., 2014). Following this model, current 
research focuses on understanding the molecular mechanisms of treatment and to 
identify potential treatment particularly for glioma. Most important role of miRNA is to 
regulate multiple 3’UTR of the mRNA. The most commonly used miRNA profiling 
methods includes northern blotting, qPCR and high-throughput microarray technology. 
Among which northern blotting and qPCR methods are specific, but their low-
throughput advents application of microarray technology form a more practical-
approach to identify novel miRNAs (Chen et al., 2009).  
miRNA microarray profiling is an efficient high through put method for identifying novel 
miRNA using a panel of miRNAs (Wang & Xi, 2013). In this study, miRNA microarray was 
carried out on duplicate samples of TMZ, 17-AAG and VER treated U87-MG. The quality 
of the extracted total RNA from U87-MG treated and untreated samples was assessed 
using Agilent 2100 Bioanalyzer confirmed excellent RNA integrity and also, 
electrophoresis verified ribosomal RNA degradation. The total RNA used for microarray 
experiments was of excellent quality. Each array was analysed using feature extraction 
software in order to carry out data normalisation to eliminate noise and multiple testing 
errors. Heat map verified correlation coefficient within and between the groups. 
Differential miRNA expression was obtained by comparing U87-MG treatment group 
including TMZ, 17-AAG and VER treated cells with U87-MG control (Untreated) as the 
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reference group. Each group was analysed using bioinformatics software. On application 
of stringent filtration, only VER-treated samples showed differential regulation with 9 
upregulated and 4 downregulated, while the other sample group showed no regulation. 
Therefore, non-stringent filtering was applied to the data (uncorrected) to identify 154 
miRNAs, 84 of which were upregulated. In order to determine potential targets, 
regulated miRNA obtained by non-stringent filtering data was also taken into 
consideration. Among which 12 upregulated miRNAs and 1 downregulated miRNA 
showed overlap between the treatments with VER and TMZ. Only one upregulated 
miRNA of 17-AAG treated sample appeared to overlap with VER and TMZ treated cells. 
Therefore, demonstrating that VER compared to 17-AAG, is a more efficient anti-
chaperone.  
miRNA target prediction algorithms follow varied models including seed match, 
conservation, free energy, and site accessibility. In order to determine the robustness of 
the algorithm for target prediction, this study further analysed the overlapped miRNAs 
with high fold difference or those subjected to stringent statistics for miRNA:mRNA 
target prediction using the statistical algorithms such as TargetScan Human 6.2, DIANA-
microT and miRBD miRBaseV18. Interestingly, as shown in Table 3.7, Hsa-miR-194-5p, 
Hsa-miR-215, Hsa-miR-449a, Hsa-miR-744-5p and Hsa-miR-3161 showed a large fold 
change between treatments. In TMZ and VER treatment, Hsa-miR-194p was upregulated 
by 139 and 63 fold, respectively, Hsa-miR-215 was upregulated 165 and 61 fold, 
respectively, Hsa-miR-449a was upregulated by 62 and 77 fold, respectively and Hsa-
miR-744-5p was upregulated by 63 and 43 fold, respectively. 17-AAG Vs Control data 
showed only one miRNA overlapping with VER Vs Control with 29 and 2 fold changes, 
respectively. Hsa-miR-4636 was the only downregulated miRNA in TMZ and VER 
treatment with a 32 and 33 fold change, respectively. Therefore, noticeable fold change 
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differences was reported in overlapping miRNAs between treatments. Also, reflecting 
similarity between miRNA regulation of TMZ and VER treatment and thereby regulating 
the same mRNA functions. Also, indicating probable similarity in mechanisms of action 
of both drugs TMZ and VER. miRNA targets more than one mRNAs, however, this study 
focused on the particular mRNAs that were validated and reported in cancer signalling 
pathways. The miRNA target prediction software identified upregulated Hsa-miR-194-
5p, Hsa-miR-215, Hsa-miR-449a, Hsa-miR-744-5p and Hsa-miR-3161 correlating to 
Dnmt3a, Alcam, Cdk4, Dnajc16 (Hsp40) and R-Ras2 genes, respectively. The targeted 
gene transcriptional levels were further validated using qRT-PCR in U87-MG treated and 
untreated cells. 
miR-194-5p, located on chromosome 1 is involved in cell migration, invasion and 
metastasis (Meng et al., 2010; Wu et al., 2014). It has been shown to be highly induced 
in some cancers such as adenocarcinoma, gastric cancer and hepatic epithelial cells 
(Chen et al., 2013). However, it is downregulated in colorectal cancer cells (HCT116), 
colon cancer, CNS tumour cell line and nephroblastomas suggesting its tumour 
suppressor role (Gaur et al., 2007; Braun et al., 2008; Kahlert et al.,  2011). However, no 
study has been published to confirm if it only functions as tumour suppressor. In glioma, 
miR-194 was reported to downregulate during hypoxia conditions (Agrawal et al., 2014). 
A recent study reported the expression of miR-194 in endometrial cancer (EC) cells 
preventing epithelial mesenchymal transition (EMT) by inhibiting its target BMI-1 and 
also inhibited tumour invasion (Kahlert et al., 2011). Likewise, it has been reported to 
be involved in TGF-β, ErbB signaling pathway and glioma and target DNMT3A (Nupur et 
al., 2012).  
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The present results show that miR-194-5p was found to be upregulated 139 and 63 fold 
in cells treated with TMZ and VER, respectively. However, its expression was not 
detected in 17-AAG treated cells. A study was carried out on miR-194-5p mRNA target 
Dnmt3a (DNA methyl transferase), where DNA methyl transferase (DNMT) family 
carried out DNA methylation at various stages to maintain gene expressions. DNMT1 
maintains DNA methylation during DNA replication, while DNMT3A and DNMT3B are 
responsible for de novo DNA methylation. Aberrations in DNA methylation causes 
genomic instability by either hypermethylation or hypomethylation (Natsume et al., 
2010; Koji et al., 2012). Transcriptional level of Dnmt3a shows no significant changes in 
TMZ and 17-AAG treated cells and marginal elevated expression in VER treatment. In 
colorectal cancer, DNMT3A levels did not show significant change compared to non-
tumour (Meng et al., 2010; Zhao et al., 2014). However, previous data illustrated 
decreased expression of DNMT3A in glioma contributing to erratic DNA methylation 
(Fanelli et al., 2008). Therefore, VER demonstrates slight improvement in the condition.  
Recent studies have shown that miR-215 is downregulated in several cancers such as 
oesophageal adenocarcinoma, colon cancer, nephroblastomas, multiple myeloma, 
demonstrating a tumour suppressor role (Deng et al., 2014), but other reports suggest  
overexpression in glioma and breast cancer (Roth et al., 2011; Lee et al., 2013). The 
elevated expression of miR-215 in breast cancer serum, osteosarcoma and colon cancer 
can lead to reduced cell proliferation, cell invasion and enhance cell cycle control (White 
et al., 2011; van Schooneveld et al., 2012; Khella et al., 2013). miR-215 expression 
reported enhance chemosensitivity in osteosarcoma and colon cancer cells (Song et al., 
2010). miR-215 was upregulated by 165 and 61 fold in cells treated with TMZ and VER, 
respectively, and below the fold change detection in cells treated with 17-AAG. miR-215 
located on chromosome 1q41 targeting adhesion molecule ALCAM reported to have 
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negative correlation in gastric epithelial cells (HFE145). They play a crucial role in 
carcinogenesis by p53 regulation and by inducing cell-cycle arrest (Jin et al., 2011). 
ALCAM (CD166), a member of immunoglobulin superfamily, mediates cell-cell adhesion 
and is suggested to be involved in cell migration, progression and differentiation in 
melanoma, prostate, colorectal and breast cancers. ALCAM expression has been 
reported to be elevated in low grade tumours while reduced in high grade tumours 
(Kristiansen et al., 2005; Hong et al., 2010). Furthermore, studies illustrated in primary 
carcinoma, ALCAM degradation leads to break down of cellular network and thereby 
increases metastasis (Jin et al., 2011). Reduced ALCAM expression has been associated 
with chemoresistance (Hong et al., 2010). Moreover, ALCAM has been found to essential 
for the activation of metalloproteinase cascade, leading to cell invasion which forms 
crucial characteristics of GBM. Studies have shown the downregulation of ALCAM in 
glioblastoma, promoting cell invasion without affecting cell proliferation rates (Kijima et 
al., 2012; Fujiwara et al., 2014). In this study, Alcam levels were enhanced by 128.8, 14.4 
and 2.6 fold in cells treated with TMZ, 17-AAG and VER, respectively. Although miRNA-
215 and the target gene Alcam were both upregulated, there was no correlation in the 
level of induction. Alcam mRNA was detected in cells treated with 17-AAG, however, 
miRNA-215 was undetected in these cells. TMZ and 17-AAG treatment was most 
effective and VER appears to enhance Alcam expression in glioma. 
miR-449 cluster located on chromosome 5 are highly conserved in humans and mice 
consist of three members, namely, miR-449a, miR-449b, miR-449c; these are 
simultaneously transcribed. miR-449 induces epithelial differentiation by inhibiting the 
Delta/Notch Pathway, whereas its inhibition reported defects in pulmonary epidermis 
differentiation. Increased levels of miR-449 has been reported in epithelial cell layer of 
choroid plexus in the brain (Feng et al., 2010; Marcet et al., 2011; Bao et al., 2012). 
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Previous reports have suggested miR-449 transcriptionally regulated Cyclin Dependent 
Kinase 6 (CDK6) by inhibiting cell progression activity in cancer cells, but also indirectly 
regulated CDK4, as its 3’UTR is not exactly the same as the miR-449 seed sequence (Yang 
et al., 2009). Reduced levels of CDK6 is associated with the inhibition of cell cycle 
progression (Feng et al., 2010). miR-449 mainly targets regulators of cell damage 
responses, cell cycle arrest, inflammation and cancer pathways (Bou Kheir et al., 2011).. 
Reduced expression of miR-449 has been observed in breast cancer MCF-7, lung 
carcinoma H1299, and noncancerous breast epithelial MCF-10A cells (Yang et al., 2009).  
The Cyclin D–CDK4/6 complex is a central component of the G1/S-phase checkpoint 
(Bou Kheir et al., 2011). miR-449 potently induces apoptosis and it also upregulates p53 
activity (Lizé et al., 2011). It suppresses tumour growth in bladder and prostate cancers 
(Noonan et al., 2009; Chen et al., 2012). The overexpression of miR-449 enhances 
chemosensitivity to cisplatin in gastric cancer cells (Hu et al., 2014). In this study, miR-
449a was induced by 62 and 77 fold in cells treated with TMZ and VER, respectively. 
Cdk4, mRNA was upregulated by 8.5, 3 and 3.5 fold in cells treated with TMZ, 17-AAG 
and VER, respectively. In contrast, Cdk4 Gene was transcriptionally induced to similar 
levels when subjected to 17-AAG and VER. The miRNA-449a was found to be induced at 
the highest level with cells treated with VER and this was below the detection level with 
cells treated with 17-AAG. Elevated levels of CDK4 has been reported in U87-MG cell 
line (Lam et al., 2000). CDKs play a role in cell cycle by interacting with cyclin-D and CDK4 
to phosphorylate Rb which in turn activates E2F genes facilitating cell cycle progression 
through G1 phase. CDK4 overexpression is associated with tumour progression in 
osteosarcomas (Schmidt et al., 2001) and gliomas (Masciullo et al., 1997; Corrias et al., 
2010; Chen et al., 2014). CDK4 and CDK6 proteins are associated with tumourigenesis 
and poor outcome in a variety of cancers. They are required for a cell to progress from 
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G1 to S phase (Schmidt et al., 2001; Bradley et al., 2014). miR-449a has been reported 
to be reduced in the U87-MG cell line acting as tumour suppressor by inhibiting cell 
growth and inducing apoptosis  (Yao et al., 2014). Previous studies have also shown the 
same tumour-suppressive function of miR-449a in bladder cancer, gastric 
adenocarcinoma, retinoblastoma and non-small cell lung cancer (Chen et al., 2012; Luo 
et al., 2013; Wei et al., 2013). Inhibiting CDK4 radiosensitised breast cancer cells have 
been carried out by inducing apoptosis with altering cell cycle progression (Hagen et al., 
2013). 
miR-744 is significantly deregulated in several cancers, including hepatocellular 
carcinoma (HCC) (Hou et al., 2011), colon cancer (Dong et al., 2013), breast cancer 
(Vislovukh et al., 2013), and gastric cancer (Song et al., 2012; Lin et al., 2014). Recent 
studies suggest miR-744 is tumour biomarker since its levels are found to be stable in 
mouse serum while upregulated in gastric cancer (Vislovukh et al., 2013). miR-744 lower 
levels in Multiple Myeloma (MM) patient serum are responsible for shorter survival 
patients (Kubiczkova et al., 2014). miR-744 negatively regulates its target transforming 
growth factor beta-1 (TGF-b1), while other target cyclinB1 is known to be positively 
targeted (Huang et al., 2011; Martin et al., 2011). Furthermore, induction of miR-744 
causes reduced cell proliferation via a transcription regulator c-Myc protein 
downregulation in HCC cell lines and cell cycle progression in HepG2 and SMMC-7721 
cells (Lin et al., 2014). In this study, miR-744-5p was enhanced on treatment with TMZ 
and VER by 63 and 43 fold, respectively. Therefore, miR expression after treatment may 
be contributing towards cancer progression and VER treatment shows an effective 
response similar to TMZ. As mentioned earlier, only two targets have been investigated 
to date. This study focused on Dnajc16 (Hsp40) as a target identified using miRNA target 
prediction software. DNAJ, also known as HSP40 is a molecular chaperone protein. It is 
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expressed in a wide variety of organisms from bacteria to humans. This family of 
proteins contains a 70 amino acid consensus sequence known as the J domain, which is 
known to interact with HSP70. The involvement of DNAJ family member Isoforms such 
as DNAJB2, DNAJB6, DNAJC5, DNAJC6, DNAJC13, and DNAJC26 in HSP70/90 chaperone 
machinery has been established (Heldens et al., 2010). Identified target of miR-744, 
namely DNAJC16 belongs to the evolutionarily conserved DNAJ/HSP40 family of proteins 
(Qiu et al., 2006). Dnajc16 mRNA was found to be upregulated by 105.6, 17.4 and 5 fold 
on treatment with TMZ, 17-AAG and VER, respectively. Again, no correlation was found 
in miRNA and mRNA targets.  As HSP40 family members act as a co-chaperone to HSP70 
machinery, they would be favourable to disrupt the HSP70/90 complex in order to 
enhance chemotherapeutic effect. Data have shown efficacy of VER treatment by 
downregulating Dnajc16 expression compared to 17-AAG and TMZ.  
miR-3161, located on chromosome 11 has been documented in laryngeal cancer cells 
where it was downregulated using paclitaxel (Xu et al., 2013). miR-3161 was the only 
miRNA that was found to be upregulated in cells treated with 17-AAG and VER by 29 and 
2 fold, respectively. R-RAS2/TC21 activates PI3K/Akt and NFκB to facilitate cell survival 
(Arora et al., 2008). It is also involved in several other cell regulatory functions such as 
cell adhesion, proliferation and migration. Limited studies carried out on R-RAS in brain 
tumours validates upregulation of RAS proteins in malignant gliomas (Nakada et al., 
2005). R-Ras was found to be over expressed in all CNS tumours and inversely 
proportional to tumour malignancy as it functions to stimulate cell survival and 
proliferation via PI3K pathway activation (Gutierrez-Erlandsson et al., 2013). miR-3161 
targets R-Ras2, located on chromosome 11p15.2, were elevated by 4.2, 7 and 8.7 fold 
in cells treated with TMZ, 17-AAG and VER, respectively. In this case, elevated R-Ras2 is 
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unfavourable as it may result in adverse conditions. Furthermore, there was no 
correlation between the upregulation of miR-3161 and R-Ras2 mRNA. 
In this study, the overall integrated analysis of miRNA and their targets show no 
significant correlation. There are several factors which can be taken into account in 
order to provide an explanation for these finding. Studies have attempted to establish 
reliability of HSP70 and HSP90 inhibitory drugs for integrated analysis of miRNA. In HeLa, 
human embryonic kidney 293T, HepG2 cells and mouse embryo fibroblasts, they have 
illustrated that molecular chaperones can enhance efficacy of the process, but are not 
mandatory for RISC loading (Pare et al., 2009). Other studies demonstrated the necessity 
of HSP70/90 requirement for RISC loading, on other hand, not for unwinding or target 
cleavage (Iwasaki et al., 2010). They stabilise Argonaute (AGO2) protein and perform 
chaperoning role for conformational changes of the AGO2 protein by ATP hydrolysis 
allowing RISC loading by recruitment of miRNA duplex. Although inhibition of HSP70/90 
affects AGO2 levels, miRNAs remain unaffected, nevertheless, it may play a role in the 
degradation of unloaded AGO2 (Martinez et al., 2013). 
Previous studies have illustrated the reliance of targeted mRNA expression on its 
complementarity. Moreover, mRNA degradation are outcome of perfect 
complementarity while silencing of protein translation, a consequence of partial 
complementarity. Despite of these, miRNA can bind onto microarray, screening miRNA 
existence in particular samples without justifying the process (Lim et al., 2005). 
However, integrated analysis of miRNA and mRNA have shown that their association can 
only be determined if targeted mRNA is completely degraded (van Iterson et al., 2013). 
Notably, miRNAs interact with 3’UTR region, but there are some exceptions showing 
binding sites in the protein coding in exons or 5’UTR regions. In some situations, RISC 
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complex necessary for mRNA degradation, is competed by ribosome-binding causing 
bridge miRNA-mediated regulation (Giraldez et al., 2006; Bartel 2009; Fabian et al., 
2010). Both In vitro and In vivo studies have demonstrated a negative relationship 
between miRNA and their target mRNA. However, positive correlation has also been 
reported (Nunez et al., 2013). Correlation studies of miRNA and their target mRNA 
inferred positive correlation may be due to the involvement of transcription factors and 
other regulating factor justifying increased expression levels in human and chimpanzee 
frontal cortex brain tissue samples (Dannemann et al., 2012). A possible explanation is 
either the effects of miRNA are overriding by other miRNA networks or they are involved 
regulatory transcription factor demonstrating unpredictability of miRNA deregulation 
throughout. Although these studies were unable to identify correlation between 
miRNAs and their targets, perhaps, research described above can help to explain the 
behaviour of mRNAs. Even though, integrated analysis was unsuccessful, investigation 
of individual target may enhance understanding of the mechanisms of treatment.  
The novel aspect of this study, as mentioned previously, was to compare the therapeutic 
efficacy of 17-AAG and VER compared to the chemotherapeutic agent, TMZ.  Gene 
expression studies have been reported in breast cancer cell lines determining 17-AAG 
(HSP90) inhibitor response (Zajac et al., 2010). Data from 17-AAG compared to control 
group have shown 4 upregulated and only 1 downregulated miRNA in non-stringent 
data, while VER compared to control data have shown 9 fold upregulation and 4 fold 
downregulation of miRNA on stringent filtering. Dysregulated miRNAs demonstrated 
overlapping of miRNAs in TMZ and VER treatment. 17-AAG and VER have a specific 
affinity towards HSP90 and HSP70, respectively. 17-AAG targets HSP90 by binding to 
nucleotide binding terminal and VER, an ATP-competitive inhibitor, selectively inhibits 
HSP70 by binding to nucleotide binding domain and also indirectly targets HSP90β. Data 
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obtained in selected mRNA transcription have reflected a close correlation in TMZ-
treated and VER-treated cells. These data validate the previous chemosensitivity assay 
in which VER treatment was more effective compared to TMZ. However, Hsp70 and 
Hsp90 transcriptional data have shown that treatment with TMZ, 17-AAG and VER does 
not support Akt activity data. Experiments involving HSP70 and HSP90 ELISA were 
carried out to confirm expression of HSPs and moreover, to validate the effect of drugs. 
The results shows that HSP70 protein activity was inhibited by 13, 0 and 20 % in TMZ, 
17-AAG and VER treatment respectively, while HSP protein was inhibited by 84, 43 and 
65 % in TMZ, 17-AAG and VER treatment respectively. The treatment with 17-AAG shows 
significant inhibition of HSP90 target while VER targeted both HSP70 and HSP90. Protein 
expression data clearly confirm affinities of HSP70 and HSP90 inhibitors. The overall data 
suggest that targeting HSP70 can be a potential therapeutic biomarker for glioblastoma.   
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 CHAPTER 5  
CONCLUSION AND FUTURE WORK 
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5.1 Conclusion  
This study has demonstrated the elevation of Hsp70 and Hsp90α in glioma cell lines 
(1321N1, GOS-3 and U87-MG) by measuring transcriptional activity compared to 
control. Since there was no significant expression of Hsp70 or Hsp90α reported in NHA 
(Normal Human Astrocytes), they were not used for further investigation. Initial results 
from this study reported induction of HSP70 on post-inhibition of HSP90 using 17-AAG. 
Therefore, HSP70 and HSP90 were targeted by VER-155008 and 17-AAG, respectively. 
Chemosensitivity was compared to standard treatment using the anticancer drug, 
Temozolomide. Furthermore, Akt kinase activity measured after treating cells with the 
relevant IC50 concentration of the drugs (TMZ, 17-AAG and VER), demonstrated of Akt 
kinase activity inhibition suggesting disruption of HSP70/90 complex. Concurrent and 
sequential chemosensitivity assays further validated the efficiency of inhibitor drugs. 
Interestingly, the activity of the inhibitory drugs was reported to be significantly higher 
in the concurrent method suggesting the ability of the drug to enhance chemosensitivity 
in glioma. Therefore, further investigations were carried out on Grade IV glioma cell line 
U87-MG.  
In order to understand the molecular mechanisms of the heat shock protein inhibitors. 
miRNA are small regulatory RNAs known to regulate several mRNAs simultaneously. 
Thereby, miRNA microarray analysis was carried out and their mRNA targets were 
determined to identify novel molecular biomarkers. miRNA microarray identified 154 
miRNAs including stringent and non-stringent data suggesting the role of miRNAs in 
glioma biology. However, no correlation was documented in miRNA and their target 
mRNA Dnmt3a, Alcam, Dnajc16 (Hsp40), Cdk4 and R-Ras2. Therefore, the application of 
miRNA technology is somewhat limited in being appropriate in predicting targets. 
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Nevertheless, the transcriptional level of selected mRNA authenticates effectivity of 17-
AAG and VER treatment. 17-AAG targets HSP90, whereas VER targets both HSP70 and 
HSP90β. HSP70 and HSP90 protein expression data confirmed the efficacy of VER and 
17-AAG. The overall data suggest that HSP90 is a softer target and HSP70 is a therapeutic 
target for treatment of glioma. 
The main findings of this study are summarised: 
1.  Established that there are enhanced Hsp70 and Hsp90 transcriptional levels in 
glioma cell lines confirmed by decreased Akt kinase activity.  
2. The chemosensitivity cell viability assay demonstrated overcome resistance in 
17-AAG and VER treatment and the combinational effect was most effective in U87-MG. 
3. Integrated analysis of miRNA: mRNA have shown no correlation in untreated and 
heat shock protein inhibitory drug treated U87-MG cell lines. 
4. VER-155008 enhances chemosensitivity in U87-MG cells. 
5. HSP70 can be a therapeutic target for glioma.  
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 Figure 5.1: Summary of the project main findings 
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5.2 Future work 
The study established HSP70 as a chemotherapeutic target in glioma. Moreover, VER-
155008, an HSP70 inhibitor, has proven to be powerful cancer therapeutic agent. A 
recent publication also supports VER-155008 as a possible therapy in non-small-cell lung 
cancer (NSCLC) (Wen et al., 2014). A report has shown its ability to induce apoptosis in 
BT474 breast cancer cells and HCT166 colon cancer cells (Massey et al., 2010). 
Therefore, measuring apoptosis using different parameters such as cytochrome-C 
caspase3/9 could be beneficial. Also, its featured ability in indirectly targeting HSP90β 
would be worth investigating. Therefore, detailed analysis of VER-155008 mode of 
action and mechanism is required in other types of cancers apart from glioma. This study 
investigated the chemotherapeutic effect of 17-AAG and VER-155008 at the molecular 
level by identifying deregulated miRNA, however, it was established that there is no 
significant correlation between miRNA and their targets. Therefore questioning the 
reliability of miRNA:mRNA integrated analysis for determining potential biomarkers. 
miRNA and their target mRNA expressions need to be verified using an anti-miR 
inhibition method. miRNA binding is proceeded irrespective of the perfect match of seed 
sequence. Thereby, it is essential to validate whether the regulation of mRNA could be 
carried out by different miRNA families. Identifying regulatory pathways involved can 
enhance understanding of miRNA regulation.  
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7.1 Gene expression in glioma cell lines 
 
Figure 7.1: Transcriptional activity of Hsp70 and Hsp90α glioma cell lines. Lane 1 and 10 represents molecular marker, lane 2 and 3 represents Hsp70 
and Hsp90 expression in NHA respectively, Lane 4 and 5 represents Hsp70 and Hsp90expression in 1321N1 respectively, Lane 6 and 7 represents Hsp70 
and Hsp90expression in U87-MG respectively, Lane 8 and 9 represents Hsp70 and Hsp90 expression in GOS-3 respectively. 
 
 
Figure 7.2: Transcriptional activity of GAPDH. Lane 1 and 6 represents molecular marker, lane 2-5 represents GAPDH expression in NHA, 1321N1, GOS-
3 and U87-MG.  
190 
 
7.2 miRNA microarray raw data 
Table 7.1: miRNAs up/down-regulated in treatment group TMZ Vs Control. 
Systematic name FC Regulation p (Corr) p mirbase accession No Chr Strand Start Stop Active sequence 
hsa-miR-215 165 up 0.06 0.000 MIMAT0000272 chr1 + 220291241 220291222 GTCTGTCAATTCATAGGTCAT 
hsa-miR-194-5p 139 up 0.08 0.001 MIMAT0000460 chr1 + 220291534 220291519 TCCACATGGAGTTGCT 
hsa-miR-550a-3p 65 up 0.33 0.003 MIMAT0003257 chr7 - 30295999 30296016 ATGTGCCTGAGGGAGTAA 
hsa-miR-769-5p 64 up 0.06 0.000 MIMAT0003886 chr19 - 46522223 46522240 AGCTCAGAACCCAGAGGTC 
hsa-miR-744-5p 63 up 0.08 0.001 MIMAT0004945 chr17 - 11985234 11985247 TGCTGTTAGCCCTA 
hsa-miR-449a 62 up 0.38 0.005 MIMAT0001541 chr5 + 54502153 54502134 ACCAGCTAACAATACACTGC 
hsa-miR-101-3p 49 up 0.61 0.021 MIMAT0000099 chr1 + 65524183 65524164 TTCAGTTATCACAGTACTGT 
hsa-miR-200c-3p 33 up 0.13 0.001 MIMAT0000617 chr12 - 7072913 7072927 TCCATCATTACCCGG 
hsa-miR-652-3p 29 up 0.17 0.002 MIMAT0003322 chrX - 109298623 109298637 CACAACCCTAGTGGC 
hsa-miR-7-1-3p 23 up 0.61 0.032 MIMAT0004553 chr9 + 86584749 86584731 TATGGCAGACTGTGATTTG 
hsa-miR-4521 23 up 0.61 0.050 MIMAT0019058 chr17 - 8090273 8090287 CTGAGCACAGGACTTC 
hsa-miR-500a-3p 19 up 0.06 0.000 MIMAT0002871 chrX - 49659834 49659851 CAGAATCCTTGCCCAGGT 
hsa-miR-4758-3p 19 up 0.53 0.008 MIMAT0019904 chr20 + 60907610 60907598 GAGGGTGGTCAGCA 
hsa-miR-557 18 up 0.06 0.000 MIMAT0003221 chr1 - 168344830 168344844 AGACAAGGCCCACCCG 
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hsa-miR-382-5p 16 up 0.61 0.037 MIMAT0000737 chr14 - 101520659 101520674 CGAATCCACCACGAAC 
hsa-miR-192-5p 5 up 0.61 0.028 MIMAT0000222 chr11 + 64658652 64658634 GGCTGTCAATTCATAGGTC 
hsa-miR-324-5p 2 up 0.61 0.037 MIMAT0000761 chr17 + 7126653 7126638 ACACCAATGCCCTAGGG 
hsa-miR-331-3p 2 up 0.54 0.010 MIMAT0000760 chr12 - 94226389 94226407 TTCTAGGATAGGCCCAGGG 
hsa-miR-148b-3p 2 up 0.61 0.040 MIMAT0000759 chr12 - 54731065 54731083 ACAAAGTTCTGTGATGCAC 
hsa-miR-3654 -73 down 0.13 0.001 MIMAT0018074 chr7 + 132719675 132719661 TTCCTCAGCTTGTCCA 
hsa-miR-335-3p -70 down 0.52 0.008 MIMAT0004703 chr7 - 130136003 130136024 GGTCAGGAGCAATAATGAAAAA 
hsa-miR-3620-5p -50 down 0.61 0.032 MIMAT0022967 chr1 - 228284997 228285007 GGCCCAGCCCAG 
hsa-miR-431-3p -42 down 0.61 0.018 MIMAT0004757 chr14 - 101347411 101347427 AGAAGCCCTGCAAGACG 
hsa-miR-4636 -32 down 0.61 0.018 MIMAT0019693 chr5 + 9053958 9053942 CTAAAGGCTTTGAACACG 
hsa-miR-193a-5p -2 down 0.38 0.005 MIMAT0004614 chr17 - 29887045 29887056 TCATCTCGCCCGC 
hsa-miR-4697-5p -2 down 0.38 0.004 MIMAT0019791 chr11 + 133768429 133768416 CACGTCAGTGACTGC 
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Table 7.2: miRNAs up/down-regulated in treatment group 17-AAG Vs Control. 
Systematic name FC Regulation p (Corr) p mirbase accession No Chr Strand Start Stop Active sequence 
hsa-miR-3161 29 up 0.67 0.007 MIMAT0015035 chr11 - 48118351 48118365 ATCTGGGCCTCTGTTC 
hsa-miR-557 19 up 0.09 0.000 MIMAT0003221 chr1 - 1.68E+08 1.68E+08 AGACAAGGCCCACCCG 
hsa-miR-3692-5p 18 up 0.67 0.009 MIMAT0018121 chr6 - 1.58E+08 1.58E+08 CAGTATCCACTCCTGAC 
hsa-miR-664b-5p 17 up 0.17 0.001 MIMAT0022271 chrX - 1.54E+08 1.54E+08 TACCCAATCATCTCCCT 
hsa-miR-345-5p -2 down 0.67 0.033 MIMAT0000772 chr14 - 1.01E+08 1.01E+08 GAGCCCTGGACTAG 
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Table 7.3: miRNAs upregulated in treatment group VER Vs Control. 
Systematic name FC Regulation p (Corr) p 
mirbase 
accession No 
Chr Strand Start Stop Active sequence 
hsa-let-7e-5p 2 up 0.21 0.012 MIMAT0000066 chr19 - 52196049 52196067 AACTATACAACCTCCTACC 
hsa-let-7g-5p 2 up 0.30 0.028 MIMAT0000414 chr3 + 52302319 52302299 AACTGTACAAACTACTACCTC 
hsa-miR-103a-3p 3 up 0.15 0.005 MIMAT0000101 chr5 + 167987970 167987953 TCATAGCCCTGTACAATG 
hsa-miR-107 2 up 0.17 0.008 MIMAT0000104 chr10 + 91352575 91352557 TGATAGCCCTGTACAATGCT 
hsa-miR-1180 24 up 0.30 0.027 MIMAT0005825 chr17 + 19247880 19247869 ACACACCCACGCG 
hsa-miR-125a-5p 3 up 0.15 0.005 MIMAT0000443 chr19 - 52196527 52196544 TCACAGGTTAAAGGGTCTC 
hsa-miR-128 3 up 0.22 0.013 MIMAT0000424 chr2 - 136423018 136423036 AAAGAGACCGGTTCACTGT 
hsa-miR-1285-3p 2 up 0.34 0.038 MIMAT0005876 chr2 + 70480122 70480106 AGGTCTCACTTTGTTGC 
hsa-miR-1306-3p 2 up 0.25 0.016 MIMAT0005950 chr22 - 20073639 20073652 CACCACCAGAGCCA 
hsa-miR-148b-3p 2 up 0.36 0.048 MIMAT0000759 chr12 - 54731065 54731083 ACAAAGTTCTGTGATGCAC 
hsa-miR-152 3 up 0.12 0.002 MIMAT0000438 chr17 + 46114600 46114586 CCAAGTTCTGTCATGC 
hsa-miR-185-5p 2 up 0.26 0.018 MIMAT0000455 chr22 - 20020681 20020697 TCAGGAACTGCCTTTCT 
hsa-miR-194-5p 63 up 0.12 0.003 MIMAT0000460 chr1 + 220291534 220291519 TCCACATGGAGTTGCT 
hsa-miR-1972 2 up 0.29 0.025 MIMAT0009447 chr16 - 70064304 70064317 TGAGCCACTGTGCC 
hsa-miR-204-5p 2 up 0.30 0.030 MIMAT0000265 chr9 + 73424944 73424925 AGGCATAGGATGACAAAGGG 
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hsa-miR-215 61 up 0.04 0.000 MIMAT0000272 chr1 + 220291241 220291222 GTCTGTCAATTCATAGGTCAT 
hsa-miR-23b-3p 2 up 0.08 0.001 MIMAT0000418 chr9 - 97847551 97847567 GGTAATCCCTGGCAATG 
hsa-miR-26a-5p 2 up 0.15 0.006 MIMAT0000082 chr3 - 38010911 38010925 AGCCTATCCTGGATT 
hsa-miR-30c-2-3p 2 up 0.29 0.023 MIMAT0004550 chr6 + 72086730 72086712 AGAGTAAACAGCCTTCTCC 
hsa-miR-30d-5p 2 up 0.29 0.026 MIMAT0000245 chr8 + 135817145 135817132 CTTCCAGTCGGGGA 
hsa-miR-30e-3p 2 up 0.19 0.010 MIMAT0000693 chr1 - 41220089 41220106 GCTGTAAACATCCGACTG 
hsa-miR-3152-3p 2 up 0.30 0.029 MIMAT0015025 chr9 - 18573350 18573369 TTATTGCCCCTATTCTAACA 
hsa-miR-3158-5p 2 up 0.28 0.021 MIMAT0019211 chr10 - 103361192 103361206 GAAGGGCTTCCTCTC 
hsa-miR-3161 2 up 0.30 0.031 MIMAT0015035 chr11 - 48118351 48118365 ATCTGGGCCTCTGTTC 
hsa-miR-324-5p 2 up 0.19 0.010 MIMAT0000761 chr17 + 7126653 7126638 ACACCAATGCCCTAGGG 
hsa-miR-342-3p 3 up 0.11 0.002 MIMAT0000753 chr14 - 100576060 100576074 ACGGGTGCGATTTCTG 
hsa-miR-3617-5p 61 up 0.04 0.000 MIMAT0017997 chr20 + 44333771 44333755 CCCATCTTGCAACTATG 
hsa-miR-374b-5p 2 up 0.34 0.038 MIMAT0004955 chrX + 73438413 73438395 CACTTAGCAGGTTGTATTA 
hsa-miR-379-5p 54 up 0.04 0.000 MIMAT0000733 chr14 - 101488413 101488428 CCTACGTTCCATAGTC 
hsa-miR-382-5p 58 up 0.15 0.005 MIMAT0000737 chr14 - 101520659 101520674 CGAATCCACCACGAAC 
hsa-miR-432-5p 2 up 0.30 0.031 MIMAT0002814 chr14 - 101350838 101350855 CCACCCAATGACCTACTC 
hsa-miR-4443 3 up 0.30 0.027 MIMAT0018961 chr3 - 48238065 48238078 AAAACCCACGCCTCC 
hsa-miR-4458 93 up 0.12 0.002 MIMAT0018980 chr5 - 8461049 8461064 TTCTTCCACACCTACCT 
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hsa-miR-4484 3 up 0.12 0.002 MIMAT0019018 chr10 - 127508379 127508391 TGGGGCTTCTCCCG 
hsa-miR-449a 77 up 0.15 0.005 MIMAT0001541 chr5 + 54502153 54502134 ACCAGCTAACAATACACTGC 
hsa-miR-449c-5p 43 up 0.30 0.031 MIMAT0010251 chr5 + 54468130 54468115 ACAGCCGCTAGCAATA 
hsa-miR-4506 43 up 0.12 0.003 MIMAT0019042 chr14 + 94414641 94414628 TTGCCTCAGACCACC 
hsa-miR-4521 56 up 0.13 0.004 MIMAT0019058 chr17 - 8090273 8090287 CTGAGCACAGGACTTC 
hsa-miR-4710 39 up 0.32 0.035 MIMAT0019815 chr14 + 105144057 105144044 AACCACCTGCCCTCA 
hsa-miR-4726-5p 2 up 0.31 0.032 MIMAT0019845 chr17 - 36875954 36875966 CCACTCCAGGCTCC 
hsa-miR-486-5p 23 up 0.30 0.029 MIMAT0002177 chr8 - 41637127 41637140 CTCGGGGCAGCTCA 
hsa-miR-493-5p 18 up 0.13 0.003 MIMAT0002813 chr14 - 101335414 101335433 AATGAAAGCCTACCATGTAC 
hsa-miR-497-5p 2 up 0.35 0.043 MIMAT0002820 chr17 + 6921273 6921256 ACAAACCACAGTGTGCTG 
hsa-miR-498 2 up 0.20 0.012 MIMAT0002824 chr19 - 54177491 54177506 GAAAAACGCCCCCTGGC 
hsa-miR-500a-3p 17 up 0.04 0.000 MIMAT0002871 chrX - 49659834 49659851 CAGAATCCTTGCCCAGGT 
hsa-miR-5010-5p 18 up 0.05 0.001 MIMAT0021043 chr17 - 40666231 40666247 AATTTTGCTCTGCCATCC 
hsa-miR-502-3p 33 up 0.04 0.000 MIMAT0004775 chrX - 49779264 49779278 TGAATCCTTGCCCAGG 
hsa-miR-5196-5p 37 up 0.28 0.021 MIMAT0021128 chr19 - 35836453 35836465 CCCAACCCTCGTCC 
hsa-miR-520c-3p 2 up 0.30 0.031 MIMAT0002846 chr19 - 54210763 54210781 ACCCTCTAAAAGGAAGCACT 
hsa-miR-532-3p 3 up 0.36 0.048 MIMAT0004780 chrX - 49767818 49767831 TGCAAGCCTTGGGTG 
hsa-miR-550a-3p 81 up 0.14 0.005 MIMAT0003257 chr7 - 30295999 30296016 ATGTGCCTGAGGGAGTAA 
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hsa-miR-6134 2 up 0.30 0.031 MIMAT0024618 chrX + 28513760 28513744 TCTACATCCTACCACCTC 
hsa-miR-652-3p 41 up 0.11 0.002 MIMAT0003322 chrX - 109298623 109298637 CACAACCCTAGTGGC 
hsa-miR-7-1-3p 61 up 0.15 0.005 MIMAT0004553 chr9 + 86584749 86584731 TATGGCAGACTGTGATTTG 
hsa-miR-744-5p 43 up 0.04 0.000 MIMAT0004945 chr17 - 11985234 11985247 TGCTGTTAGCCCTA 
hsa-miR-758-5p 3 up 0.15 0.005 MIMAT0022929 chr14 - 101492379 101492392 GTGTGCTCTCTGGTC 
hsa-miR-769-5p 48 up 0.13 0.004 MIMAT0003886 chr19 - 46522223 46522240 AGCTCAGAACCCAGAGGTC 
hsa-miR-885-5p 29 up 0.04 0.000 MIMAT0004947 chr3 + 10436204 10436189 AGAGGCAGGGTAGTGTA 
hsa-miR-9-5p 2 up 0.34 0.040 MIMAT0000441 chr1 + 156390170 156390152 TCATACAGCTAGATAACCA 
hsa-miR-98-5p 3 up 0.34 0.038 MIMAT0000096 chrX + 53583226 53583206 AACAATACAACTTACTACCTC 
 
  
197 
 
Table 7.4: miRNAs downregulated in treatment group VER Vs Control. 
Systematic name FC Regulation p (Corr) p 
mirbase 
accession No 
Chr Strand Start Stop Active sequence 
dmr_285 -2 down 0.0 0.000       
hsa-miR-10b-3p -31 down 0.1 0.006 MIMAT0004556 chr2 - 177015099 177015117 ATTCCCCTAGAATCGAATC 
hsa-miR-1225-5p -3 down 0.1 0.003 MIMAT0005572 chr16 + 2140217 2140208 CCCCCCACTGG 
hsa-miR-1227-5p -3 down 0.1 0.006 MIMAT0022941 chr19 + 2234077 2234067 CCACCGCCTGGC 
hsa-miR-1234-3p -3 down 0.3 0.018 MIMAT0005589 chr8 + 145625557 145625547 GTGGGGTGGGT 
hsa-miR-1234-5p -2 down 0.2 0.008 MIMAT0022944 chr8 + 145625513 145625504 CGGCCCCCCCC 
hsa-miR-135a-3p -5 down 0.2 0.009 MIMAT0004595 chr3 + 52328311 52328299 CGCCACGGCTCCA 
hsa-miR-138-2-3p -3 down 0.2 0.006 MIMAT0004596 chr16 - 56892492 56892507 AACCCTGGTGTCGTGA 
hsa-miR-139-3p -4 down 0.1 0.001 MIMAT0004552 chr11 + 72326171 72326157 ACTCCAACAGGGCCG 
hsa-miR-1469 -10 down 0.0 0.000 MIMAT0007347 chr15 - 96876502 96876511 GGAGCCCGCGC 
hsa-miR-1587 -2 down 0.3 0.025 MIMAT0019077 chrX - 39696824 39696835 CCCAACCCAGCCC 
hsa-miR-1915-3p -3 down 0.2 0.016 MIMAT0007892 chr10 + 21785556 21785546 CCCGCCGCGTC 
hsa-miR-197-5p -2 down 0.3 0.026 MIMAT0022691 chr1 - 110141534 110141545 CCTCCCACTGCCC 
hsa-miR-2861 -3 down 0.2 0.008 MIMAT0013802 chr9 - 130548259 130548268 CCGCCCACCGC 
hsa-miR-3137 -2 down 0.2 0.010 MIMAT0015005 chr3 + 194855264 194855251 ACCCCATTGCTCCCA 
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hsa-miR-3188 -2 down 0.3 0.030 MIMAT0015070 chr19 - 18392950 18392961 CCCCGTATCCGCA 
hsa-miR-3196 -3 down 0.1 0.004 MIMAT0015080 chr20 - 61870146 61870157 GAGGCCCCTGCCG 
hsa-miR-3663-3p -2 down 0.3 0.029 MIMAT0018085 chr10 + 118927268 118927259 GCGCCCGGCCT 
hsa-miR-371b-5p -3 down 0.2 0.008 MIMAT0019892 chr19 + 54290958 54290945 AAAGTGCCGCCATCT 
hsa-miR-3940-5p -2 down 0.3 0.024 MIMAT0019229 chr19 + 6416462 6416452 CAGAGCCCGCCC 
hsa-miR-4428 -3 down 0.2 0.016 MIMAT0018943 chr1 - 237634473 237634485 GCTCCATGTTCCCG 
hsa-miR-4430 -3 down 0.3 0.040 MIMAT0018945 chr2 - 33643591 33643603 CTCCGCTCACTCCA 
hsa-miR-4446-3p -3 down 0.3 0.041 MIMAT0018965 chr3 - 113313773 113313786 ACCCATGTCACTGCC 
hsa-miR-4462 -3 down 0.4 0.045 MIMAT0018986 chr6 + 37523197 37523185 TTCCCAAGCCACCC 
hsa-miR-4478 -2 down 0.1 0.004 MIMAT0019006 chr9 + 124882381 124882368 CTCCTCAGCTCAGCC 
hsa-miR-4505 -2 down 0.1 0.006 MIMAT0019041 chr14 - 74225458 74225469 TCCGTCCCAGCCC 
hsa-miR-4507 -2 down 0.3 0.024 MIMAT0019044 chr14 + 106324343 106324333 CCCAGCCCAGCC 
hsa-miR-4515 -2 down 0.3 0.021 MIMAT0019052 chr15 - 83736112 83736122 GGGCTGCCGGGA 
hsa-miR-4530 -3 down 0.1 0.001 MIMAT0019069 chr19 + 39900312 39900301 CGCTCCCGTCCTG 
hsa-miR-4532 -2 down 0.1 0.001 MIMAT0019071 chr20 - 56470462 56470471 CGCCGGGCTCC 
hsa-miR-4538 -2 down 0.3 0.028 MIMAT0019081     TCAGCCCAGCTCATC 
hsa-miR-4634 -3 down 0.3 0.022 MIMAT0019691 chr5 - 174178755 174178764 CCCCGGGCCGG 
hsa-miR-4636 -33 down 0.3 0.019 MIMAT0019693 chr5 + 9053958 9053942 CTAAAGGCTTTGAACACG 
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hsa-miR-4647 -26 down 0.1 0.004 MIMAT0019709 chr6 + 44221975 44221961 TTCCTCAGCACAGCAC 
hsa-miR-4656 -2 down 0.3 0.036 MIMAT0019723 chr7 + 4828227 4828215 ACAGGCCTCCTGCC 
hsa-miR-4665-5p -3 down 0.1 0.002 MIMAT0019739 chr9 - 6007846 6007857 GCTCGCGCTCACG 
hsa-miR-4721 -2 down 0.1 0.003 MIMAT0019835 chr16 + 28855320 28855308 CCACCGTCACCTGG 
hsa-miR-4728-5p -2 down 0.1 0.002 MIMAT0019849 chr17 - 37882758 37882771 TGCTTGCTGCCTCTC 
hsa-miR-4739 -2 down 0.3 0.035 MIMAT0019868 chr17 + 77681018 77681007 AGGGCCCCTCCGC 
hsa-miR-4741 -2 down 0.1 0.003 MIMAT0019871 chr18 - 20513381 20513392 AGCCGACCCCTCC 
hsa-miR-4767 -42 down 0.2 0.011 MIMAT0019919 chrX - 7065923 7065932 GGCGGCGGCCA 
hsa-miR-4787-3p -37 down 0.0 0.000 MIMAT0019957 chr3 - 50712575 50712584 GCGCGGGGCAG 
hsa-miR-4787-5p -3 down 0.1 0.003 MIMAT0019956 chr3 - 50712535 50712545 GGGATGCCGCCG 
hsa-miR-5001-5p -2 down 0.2 0.008 MIMAT0021021 chr2 + 233415227 233415216 AGCTCCGCCGCTG 
hsa-miR-5006-5p -2 down 0.4 0.046 MIMAT0021033 chr13 + 42142462 42142449 TTCCACCTCCTGCCC 
hsa-miR-503-5p -52 down 0.3 0.022 MIMAT0002874 chrX + 133680385 133680368 CTGCAGAACTGTTCCCGC 
hsa-miR-513a-5p -3 down 0.0 0.000 MIMAT0002877 chrX + 146295034 146295019 ATGACACCTCCCTGTG 
hsa-miR-513b -3 down 0.1 0.004 MIMAT0005788 chrX + 146280596 146280579 ATAAATGACACCTCCTTGT 
hsa-miR-513c-5p -3 down 0.1 0.004 MIMAT0005789 chrX + 146271256 146271238 ATAAACGACACCTCCTTGA 
hsa-miR-548q -126 down 0.1 0.003 MIMAT0011163 chr10 + 12767281 12767267 CCGCCATTACTTTTGC 
hsa-miR-5585-3p -96 down 0.1 0.006 MIMAT0022286 chr1 - 32552594 32552608 ACCTGTAGTCCCAGCT 
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hsa-miR-575 -4 down 0.1 0.003 MIMAT0003240 chr4 + 83674568 83674552 GCTCCTGTCCAACTGGCT 
hsa-miR-6068 -4 down 0.1 0.002 MIMAT0023693 chr1 + 63792616 63792606 CCACCGCCGGAG 
hsa-miR-6089 -3 down 0.3 0.028 MIMAT0023714 chrX - 2527283 2527293 CCGCCCCGCCC 
hsa-miR-6090 -2 down 0.3 0.021 MIMAT0023715 chr11 - 128392334 128392343 GCCCCGCCCCT 
hsa-miR-6125 -3 down 0.1 0.004 MIMAT0024598 chr12 - 62654208 62654218 TCCGCCGCTCCG 
hsa-miR-638 -3 down 0.3 0.019 MIMAT0003308 chr19 - 10829107 10829119 AGGCCGCCACCCGC 
hsa-miR-650 -15 down 0.4 0.047 MIMAT0003320 chr22 - 23165291 23165305 GTCCTGAGAGCGCTGC 
hsa-miR-6722-3p -2 down 0.3 0.042 MIMAT0025854 chr9 + 139641412 139641402 CCTGGCCCACCC 
hsa-miR-718 -9 down 0.3 0.036 MIMAT0012735 chrX + 153285432 153285423 CGACGCCCGGC 
hsa-miR-921 -6 down 0.4 0.044 MIMAT0004971 chr1 + 166124005 166123990 GAATCCTGGTTCTGTCC 
hsa-miR-940 -4 down 0.3 0.020 MIMAT0004983 chr16 - 2321817 2321827 GGGGAGCGGGGG 
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7.3 Primer Design 
 
Figure 7.3: Gene location of Dnmt3a using GeneCards database. Red bar represents 
location of Dnmt3a. 
 
Figure 7.4: mRNA sequence of Dnmt3a & the locations of the primers using NCBI 
database. Primer locations have been highlighted in blues and yellow indicating sense 
and antisense primers, respectively. 
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Figure 7.5: Primer design of Dnmt3a gene using Primer3Plus. The output page of 
Primer3 provides the right and the left primers. 
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 Figure 7.6: Gene location of Alcam using GeneCards database. Red bar represents 
location of Alcam. 
 
Figure 7.7: mRNA sequence of Alcam & the locations of the primers using NCBI 
database. Primer locations have been highlighted in blues and yellow indicating sense 
and antisense primers, respectively. 
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 Figure 7.8: Primer design of Alcam gene using Primer3Plus. The output page of Primer3 
provides the right and the left primers. 
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 Figure 7.9: Gene location of Cdk4 using GeneCards database. Red bar represents 
location of Cdk4. 
 
 
Figure 7.10: mRNA sequence of Cdk4 & the locations of the primers using NCBI 
database. Primer locations have been highlighted in blues and yellow indicating sense 
and antisense primers, respectively. 
 
Figure 7.11: Primer design of Cdk4 gene using Primer3Plus. The output page of Primer3 
provides the right and the left primers. 
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Figure 7.12: Gene location of Dnajc16 (Hsp40) using GeneCards database. Red bar 
represents location of Dnajc16(Hsp40). 
 
 
Figure 7.13: mRNA sequence of Dnajc16 (Hsp40) & the locations of the primers using 
NCBI database. Primer locations have been highlighted in blues and yellow indicating 
sense and antisense primers, respectively. 
 
Figure 7.14: Primer design of Dnajc16 (Hsp40) gene using Primer3Plus. The output page 
of Primer3 provides the right and the left primers. 
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Figure 7.15: Gene location of R-Ras2 using GeneCards database. Red bar represents 
location of R-Ras2. 
 
 
Figure 7.16: mRNA sequence of R-Ras2 & the locations of the primers using NCBI 
database. Primer locations have been highlighted in blues and yellow indicating sense 
and antisense primers, respectively. 
 
Figure 7.17: Primer design of R-Ras2 gene using Primer3Plus. The output page of 
Primer3 provides the right and the left primers.  
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7.4 Gene expression of predicted target mRNA 
 
Figure 7.18: Agarose gel electrophoresis of predicted miRNA targets. lane 1 and 6 
represents the 100 bp molecular marker, lane 2 represents Untreated control, lane 3 
TMZ-treated U87-MG, lane 4 represents 17-AAG-treated U87-MG and lane 5 represents 
VER-treated U87-MG. (A) Dnmt3a (B) Alcam (C) Cdk4 (D) Dnajc16 (Hsp40) (E) R-Ras2 (F) 
Hsp70 (G) Hsp90α. 
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